<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diazepam: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diazepam: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Diazepam: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12370" href="/d/html/12370.html" rel="external">see "Diazepam: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13223" href="/d/html/13223.html" rel="external">see "Diazepam: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F50711533"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">FDA Extends Expiration Dates for Certain Meridian Autoinjectors: Updated</span>
<span class="collapsible-date">July 2017</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-top:2em;">The FDA is alerting health care providers and emergency responders that certain lots of <i>AtroPen</i> (atropine), <i>CANA</i> (diazepam), morphine sulfate, and pralidoxime chloride autoinjectors manufactured by Meridian Medical Technologies can be used beyond the labeled expiration date, which should help mitigate potential shortages of these drugs. To ensure patient safety, products should be stored under the manufacturer’s labeled storage conditions.</p>
<p style="text-indent:0em;margin-top:2em;">Additional information may be found at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2FDrugs%2FDrugSafety%2Fucm376367.htm&amp;token=SHauxSdf9qNc6lLK16E8IDV3KxAgJ9eAUWFzIj8OhB%2BDS1QnG3nll2ktzEV1bFFqNvp%2FS6dk6auUFKQXeUZdHA%3D%3D&amp;TOPIC_ID=9345" target="_blank">http://www.fda.gov/Drugs/DrugSafety/ucm376367.htm</a>.</p></div>
</div>
</div>
<div class="block black-box-warn drugH1Div" id="F49351801"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Risks from concomitant use with opioids:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Abuse, misuse, and addiction:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The use of benzodiazepines, including diazepam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing diazepam and throughout treatment, assess each patient's risk for abuse, misuse, and addiction.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dependence and withdrawal reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Oral: The continued use of benzodiazepines, including diazepam, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of diazepam after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue diazepam or reduce the dosage.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, nasal spray, rectal gel: The continued use of benzodiazepines, including diazepam, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Although diazepam is indicated only for intermittent use, if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction may precipitate acute withdrawal reactions, which can be life-threatening. For patients using diazepam more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue diazepam.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F159030"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Diastat AcuDial [DSC];</li>
<li>Diastat Pediatric [DSC];</li>
<li>diazePAM Intensol;</li>
<li>Valium;</li>
<li>Valtoco 10 MG Dose;</li>
<li>Valtoco 15 MG Dose;</li>
<li>Valtoco 20 MG Dose;</li>
<li>Valtoco 5 MG Dose</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866573"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Diastat;</li>
<li>PMS-Diazepam [DSC];</li>
<li>Valium</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F159080"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiseizure Agent, Benzodiazepine;</li>
<li>
                        Benzodiazepine</li></ul></div>
<div class="block doa drugH1Div" id="F159035"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Reduce dose or avoid use in patients receiving opioids or with significant chronic disease (eg, respiratory compromise). Avoid use in patients with a history of substance use, misuse of medications, or depression, except for acute or emergency situations (eg, status epilepticus) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26900382','lexi-content-ref-Craske.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26900382','lexi-content-ref-Craske.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="681d778e-2c1e-46c3-9264-d477867f0a71">Anxiety</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anxiety:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Anxiety, acute/severe (monotherapy or adjunctive therapy): </b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM, IV, Oral:</b> 2 to 10 mg every 3 to 6 hours as needed up to 40 mg/day; adjust dose based on response and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Craske.1','lexi-content-ref-Roy-Byrne.1','lexi-content-ref-35900161']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Craske.1','lexi-content-ref-Roy-Byrne.1','lexi-content-ref-35900161'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Anxiety disorders (monotherapy or adjunctive therapy) (alternative agent):</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Generally used short term for symptom relief until preferred therapy (eg, serotonin reuptake inhibitor) is effective (eg, 4 to 6 weeks, followed by tapering). Long-term, low-dose (eg, 2.5 mg/day) therapy may be considered in select patients only when other treatments are ineffective or poorly tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Craske.1','lexi-content-ref-25081580','lexi-content-ref-35900161']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Craske.1','lexi-content-ref-25081580','lexi-content-ref-35900161'])">Ref</a></span>). Use with caution in patients with posttraumatic stress disorder; benzodiazepines may worsen symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-VADOD.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-VADOD.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: <b>Oral:</b> 2 to 5 mg once or twice daily; increase gradually based on response and tolerability up to 40 mg/day in 2 to 4 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Craske.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Craske.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Procedural anxiety (premedication): </b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 2 to 10 mg <b>or</b> 0.03 to 0.1 mg/kg once (maximum single dose: 10 mg) 5 to 15 minutes prior to procedure; if needed due to incomplete response and/or duration of procedure, may repeat the dose (usually 50% of the initial dose) after 5 to 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Choy.1','lexi-content-ref-1473667','lexi-content-ref-10343209']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Choy.1','lexi-content-ref-1473667','lexi-content-ref-10343209'])">Ref</a></span>).<b> Note:</b> In obese patients, non-weight-based dosing is preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Choy.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Choy.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral (off-label):</b> 2 to 10 mg once 30 to 60 minutes prior to procedure; if needed due to incomplete response, may repeat the dose (usually 50% of the initial dose) after 30 to 60 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Choy.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Choy.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ffd62b4-0844-460d-a11e-8aee71d408a4">Hydroxychloroquine/chloroquine toxicity</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hydroxychloroquine/chloroquine toxicity (severe): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Use is recommended in patients with severe toxicity (eg, hypotension, QTc prolongation, hypokalemia) in combination with other supportive measures (eg, mechanical ventilation, epinephrine, cardiovascular monitoring) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barry.2019','lexi-content-ref-18180661','lexi-content-ref-11555803','lexi-content-ref-26351590','lexi-content-ref-3336379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barry.2019','lexi-content-ref-18180661','lexi-content-ref-11555803','lexi-content-ref-26351590','lexi-content-ref-3336379'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>2 mg/kg once administered over 30 minutes, followed by 1 to 2 mg/kg/day for 2 to 4 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barry.2019','lexi-content-ref-11555803']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barry.2019','lexi-content-ref-11555803'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d93e0d56-b2c1-4c09-9d4b-fabe64541e4d">Intoxication</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intoxication (cocaine, methamphetamine, and other sympathomimetics) (off-label use):</b> Based on limited data.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 to 10 mg every 3 to 10 minutes as needed for agitation, sedation, seizures, hypertension, and tachycardia until desired symptom control achieved; doses up to 20 mg may be considered in severe agitation based on response and tolerability. Large, cumulative doses may be required for some patients; monitor for respiratory depression and hypotension. <b>Note</b>
<b>: </b>If IV access is not possible, consider IM administration; however, IM diazepam time to peak drug levels is slower than IM midazolam (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Arnold.1','lexi-content-ref-Boyer.1','lexi-content-ref-Delgado.1','lexi-content-ref-2179901','lexi-content-ref-28297728']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Arnold.1','lexi-content-ref-Boyer.1','lexi-content-ref-Delgado.1','lexi-content-ref-2179901','lexi-content-ref-28297728'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4a6fcb4e-9771-4d04-bfde-accb45fdd51d">Muscle spasm, spasticity, and/or rigidity</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Muscle spasm, spasticity, and/or rigidity (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 2 mg twice daily <b>or</b> 5 mg at bedtime; increase gradually based on response and tolerability, up to 40 to 60 mg/day in 3 to 4 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Abrams.1','lexi-content-ref-10776831','lexi-content-ref-Olek.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Abrams.1','lexi-content-ref-10776831','lexi-content-ref-Olek.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cb3c9c3d-af3b-4e18-902e-e0c1117bc1a7">Neuroleptic malignant syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroleptic malignant syndrome (adjunctive therapy) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Following withdrawal of causative agent while continuing supportive care, use for moderate to severe muscle rigidity with elevated creatine kinase. May also use for any patient experiencing agitation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wijdicks.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wijdicks.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 10 mg every 8 hours until symptom resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20979709','lexi-content-ref-Wijdicks.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20979709','lexi-content-ref-Wijdicks.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3bdc9ea7-289f-4752-8056-e3eef3f779c9">Seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>If IV access is not available<b>, </b>IM diazepam is not recommended due to erratic absorption and slow time to peak drug levels (IM midazolam is recommended) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26071998','lexi-content-ref-4033223']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26071998','lexi-content-ref-4033223'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Acute active seizures (non-status epilepticus):</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Intranasal:</b> 0.2 mg/kg as a single dose; may repeat once based on response and tolerability after ≥4 hours. Maximum dose: Two doses per episode. Do not use for more than 1 episode every 5 days or more than 5 episodes per month.</p>
<p style="text-indent:-2em;margin-left:8em;">The following table (derived from manufacturer labeling) provides acceptable weight ranges for each dose, such that patients will receive between 90% and 180% of the calculated recommended dose.</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center" colspan="4">
<p style="text-indent:0em;">Recommended Intranasal Diazepam Dosage for Adults</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">Weight</p></th>
<th align="center">
<p style="text-indent:0em;">Dose (rounded from 0.2 mg/kg)</p></th>
<th align="center">
<p style="text-indent:0em;">Number of nasal spray devices</p></th>
<th align="center">
<p style="text-indent:0em;">Number of sprays</p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">28 to 50 kg</p></td>
<td align="center">
<p style="text-indent:0em;">10 mg</p></td>
<td align="center">
<p style="text-indent:0em;">One 10 mg device</p></td>
<td align="center">
<p style="text-indent:0em;">One spray in one nostril</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">51 to 75 kg</p></td>
<td align="center">
<p style="text-indent:0em;">15 mg</p></td>
<td align="center">
<p style="text-indent:0em;">Two 7.5 mg devices</p></td>
<td align="center">
<p style="text-indent:0em;">One spray in each nostril</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">76 kg and up</p></td>
<td align="center">
<p style="text-indent:0em;">20 mg</p></td>
<td align="center">
<p style="text-indent:0em;">Two 10 mg devices</p></td>
<td align="center">
<p style="text-indent:0em;">One spray in each nostril</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 5 to 10 mg as a single dose given at a maximum infusion rate of 5 mg/minute; may repeat at 3- to 5-minute intervals up to a total dose of 30 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Drislane.1','lexi-content-ref-22528274','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Drislane.1','lexi-content-ref-22528274','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Rectal gel (generally for use in prehospital setting):</b> 0.2 mg/kg (round dose up to the nearest 2.5 mg increment; maximum dose: 20 mg) <b>or </b>10 to 20 mg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Drappatz.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Drappatz.1','lexi-content-ref-Manu.1'])">Ref</a></span>). Maximum duration: 5 episodes/month and 1 episode every 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Status epilepticus (alternative agent):</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 5 to 10 mg as a single dose given at a maximum infusion rate of 5 mg/minute; may repeat dose in 3 to 5 minutes if seizures continue; a nonbenzodiazepine antiseizure agent should follow to prevent seizure recurrence, even if seizures have ceased (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26900382','lexi-content-ref-Drislane.1','lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26900382','lexi-content-ref-Drislane.1','lexi-content-ref-22528274'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Rectal gel (generally for use in prehospital setting) (off-label):</b> 0.2 to 0.5 mg/kg (round dose up to the nearest 2.5 mg increment; maximum dose: 20 mg) as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26900382','lexi-content-ref-Drislane.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26900382','lexi-content-ref-Drislane.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bce45f2d-590a-4d58-a2ee-8620e421f49b">Serotonin syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Serotonin syndrome (serotonin toxicity) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 5 to 10 mg every 8 to 10 minutes until symptoms resolve (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Boyer.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Boyer.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5aaf2b38-7731-4c1e-a1d0-efefaf9b21a5">Substance withdrawal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Substance withdrawal:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Alcohol withdrawal syndrome:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Withdrawal will progress at different rates in some patients; flexibility in dosing and duration is warranted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hoffman.1','lexi-content-ref-VADOD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hoffman.1','lexi-content-ref-VADOD.1'])">Ref</a></span>). Regimens vary and depend on withdrawal history, degree of current withdrawal symptoms, blood alcohol concentration, and whether the patient is treated inpatient or in the ambulatory setting. Many facilities only treat alcohol withdrawal in the ambulatory setting if Clinical Institute Withdrawal Assessment for Alcohol, revised scale (CIWA-Ar) score is ≤15 (mild to moderate alcohol withdrawal) and there is no history of withdrawal seizures or delirium tremens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511109','lexi-content-ref-Holt.1','lexi-content-ref-33224688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511109','lexi-content-ref-Holt.1','lexi-content-ref-33224688'])">Ref</a></span>). Some experts recommend avoiding IM administration due to variable absorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28101764']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28101764'])">Ref</a></span>). The following are two suggested regimens.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Symptom-triggered regimen:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Some experts recommend inpatient treatment and symptom-triggered dosing for patients with CIWA-Ar &gt;15 (moderate to severe alcohol withdrawal) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511109','lexi-content-ref-Hoffman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511109','lexi-content-ref-Hoffman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV, Oral:</b> 5 to 10 mg as needed per institution-specific protocol until appropriate sedation achieved; dose and frequency determined by withdrawal symptom severity using a validated severity assessment scale, such as the CIWA-Ar (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hoffman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hoffman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Fixed-dose regimen</i>
<i>:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Some experts recommend fixed-dose regimens for patients with CIWA-Ar ≤15 (mild to moderate alcohol withdrawal) (Holt 2023). In addition to scheduled doses shown in the example regimen below, provide up to 5 additional as-needed 10 mg doses to be used over the 4-day treatment period for symptom-triggered dosing (Holt 2023).</p>
<p style="text-indent:-2em;margin-left:10em;">Day 1: <b>Oral, IV: </b>10 mg every 6 hours (Holt 2023; WFSBP [Soyka 2017]).</p>
<p style="text-indent:-2em;margin-left:10em;">Day 2: <b>Oral, IV: </b>10 mg every 8 hours (Holt 2023; WFSBP [Soyka 2017]).</p>
<p style="text-indent:-2em;margin-left:10em;">Day 3: <b>Oral, IV: </b>10 mg every 12 hours (Holt 2023; WFSBP [Soyka 2017]).</p>
<p style="text-indent:-2em;margin-left:10em;">Day 4: <b>Oral, IV: </b>10 mg at bedtime, then discontinue diazepam (Holt 2023; WFSBP [Soyka 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Opioid withdrawal (autonomic instability and agitation) (alternative agent) (adjunctive therapy) (off-label use):</b></i> Based on limited data.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 10 to 20 mg every 5 to 10 minutes until hemodynamically stable and adequate sedation achieved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stolbach.2019','lexi-content-ref-29605483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stolbach.2019','lexi-content-ref-29605483'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0cafbc8a-abd9-42c0-9a5e-50ae32938929">Vertigo, acute episodes</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vertigo, acute episodes (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Reserve use for symptomatic relief of episodes lasting several hours to days (maximum duration: 3 days); chronic use may impede adaptation and recovery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Furman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Furman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral:</b> 1 to 5 mg every 12 hours as needed for up to 48 to 72 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Furman.1','lexi-content-ref-12521357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Furman.1','lexi-content-ref-12521357'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Discontinuation of therapy</b>: Unless safety concerns require a more rapid withdrawal, gradually taper to detect reemerging symptoms and minimize rebound and withdrawal symptoms in patients receiving therapy ≥4 weeks or as appropriate based on patient-specific factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21714826','lexi-content-ref-VADOD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21714826','lexi-content-ref-VADOD.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Low or moderate dose, no concerns for benzodiazepine use disorder</b>: Taper total daily dose by 20% to 25% every week based on response and tolerability (taper increments will be limited by available dosage forms) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Craske.1','lexi-content-ref-VADOD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Craske.1','lexi-content-ref-VADOD.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extended or high-dose therapy, or suspected benzodiazepine use disorder:</b> Taper total daily dose by approximately 25% every 1 to 2 weeks based on response, tolerability, and individual patient factors (taper increments will be limited by available dosage forms) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Park.1','lexi-content-ref-VADOD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Park.1','lexi-content-ref-VADOD.1'])">Ref</a></span>). Reduce dose more rapidly in the beginning, and slow the dose reduction as the taper progresses because earlier stages of withdrawal are easier to tolerate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21714826','lexi-content-ref-VADOD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21714826','lexi-content-ref-VADOD.1'])">Ref</a></span>). The optimal duration and taper increment will vary; up to 6 months may be necessary for some patients on higher doses, and a taper rate of 50% every week may be tolerated in some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Park.1','lexi-content-ref-VADOD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Park.1','lexi-content-ref-VADOD.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990803"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> An increased incidence of CNS-related adverse effects has been reported in patients with hypoalbuminemia (which is frequently observed in patients with end-stage kidney disease or critical illness) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4851053']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4851053'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney impairment; use with caution, especially with prolonged courses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7340884','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7340884','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzable (highly protein bound, large V<sub>d</sub>): No supplemental dose or dosage adjustment necessary; use with caution, especially with prolonged courses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7340884','lexi-content-ref-6145109','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7340884','lexi-content-ref-6145109','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis: </b>Unlikely to be significantly dialyzable (highly protein bound, large V<sub>d</sub>): No dosage adjustment necessary; use with caution, especially with prolonged courses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>No dosage adjustment necessary; use with caution, especially with prolonged courses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary; use with caution, especially with prolonged courses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988002"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution because distribution and half-life may increase, and clearance may decrease significantly. The oral tablets are contraindicated in severe hepatic impairment.</p></div>
<div class="block doe drugH1Div" id="F159036"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Avoid use, may be appropriate for seizure disorders, alcohol withdrawal, severe generalized anxiety disorder, or periprocedural anesthesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Older and/or debilitated patients:</p>
<p style="text-indent:-2em;margin-left:4em;">IM, IV: Initial: 2 to 5 mg; increase gradually based on response and tolerability.</p>
<p style="text-indent:-2em;margin-left:4em;">Intranasal: Due to the increased half-life in elderly patients, consider reducing dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Initial: 2 to 2.5 mg 1 to 2 times daily; increase gradually based on response and tolerability.</p>
<p style="text-indent:-2em;margin-left:4em;">Rectal gel: Due to the increased half-life in elderly and debilitated patients, consider reducing dose.</p></div>
<div class="block dop drugH1Div" id="F159055"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13223" href="/d/html/13223.html" rel="external">see "Diazepam: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="447ae2a2-0136-4435-ad36-dcd980b67001">Seizures, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures, acute: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Intranasal: Dosing varies with age; patients &lt;12 years require a larger mg/kg/dose. May repeat dose in 4 hours; do not exceed 2 doses in 24 hours. Do not repeat dose if patient has difficulty breathing or excessive sedation. Do not exceed maximum treatment frequency of 1 episode <b>every 5 days</b> and 5 episodes per month.</p>
<p style="text-indent:-2em;margin-left:6em;">Children 6 to 11 years:</p>
<table border="1" frame="border" rules="all">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Weight</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Dose (mg)</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Quantity and Type of Nasal Device</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Number of Sprays</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">10 to &lt;19 kg</p></td>
<td align="center">
<p style="text-indent:0em;">5 mg</p></td>
<td align="center">
<p style="text-indent:0em;">One 5 mg device</p></td>
<td align="center">
<p style="text-indent:0em;">1 spray in 1 nostril</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">19 to &lt;38 kg</p></td>
<td align="center">
<p style="text-indent:0em;">10 mg</p></td>
<td align="center">
<p style="text-indent:0em;">One 10 mg device</p></td>
<td align="center">
<p style="text-indent:0em;">1 spray in 1 nostril</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">38 to &lt;56 kg</p></td>
<td align="center">
<p style="text-indent:0em;">15 mg</p></td>
<td align="center">
<p style="text-indent:0em;">Two 7.5 mg devices</p></td>
<td align="center">
<p style="text-indent:0em;">2 sprays delivered as 1 spray in each nostril</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">56 to 74 kg</p></td>
<td align="center">
<p style="text-indent:0em;">20 mg</p></td>
<td align="center">
<p style="text-indent:0em;">Two 10 mg devices</p></td>
<td align="center">
<p style="text-indent:0em;">2 sprays delivered as 1 spray in each nostril</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents:</p>
<table border="1" frame="border" rules="all">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Weight</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Dose (mg)</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Quantity and Type of Nasal Device</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Number of Sprays</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">14 to &lt;28 kg</p></td>
<td align="center">
<p style="text-indent:0em;">5 mg</p></td>
<td align="center">
<p style="text-indent:0em;">One 5 mg device</p></td>
<td align="center">
<p style="text-indent:0em;">1 spray in 1 nostril</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">28 to &lt;51 kg</p></td>
<td align="center">
<p style="text-indent:0em;">10 mg</p></td>
<td align="center">
<p style="text-indent:0em;">One 10 mg device</p></td>
<td align="center">
<p style="text-indent:0em;">1 spray in 1 nostril</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">51 to &lt;76 kg</p></td>
<td align="center">
<p style="text-indent:0em;">15 mg</p></td>
<td align="center">
<p style="text-indent:0em;">Two 7.5 mg devices</p></td>
<td align="center">
<p style="text-indent:0em;">2 sprays delivered as 1 spray in each nostril</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">≥76 kg</p></td>
<td align="center">
<p style="text-indent:0em;">20 mg</p></td>
<td align="center">
<p style="text-indent:0em;">Two 10 mg devices</p></td>
<td align="center">
<p style="text-indent:0em;">2 sprays delivered as 1 spray in each nostril</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Rectal gel formulation:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Weight-based dosing:</i>
<b>Note:</b> Round dose up to the nearest 2.5 mg increment. Do not use more than 5 times per month or for more than 1 episode every 5 days.</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children 6 months to &lt;2 years: Rectal: Dose not established.</p>
<p style="text-indent:-2em;margin-left:8em;">Children 2 to 5 years: Rectal: 0.5 mg/kg; maximum dose: 20 mg/dose; dose may be repeated in 4 to 12 hours if needed.</p>
<p style="text-indent:-2em;margin-left:8em;">Children 6 to 11 years: Rectal: 0.3 mg/kg; maximum dose: 20 mg/dose; dose may be repeated in 4 to 12 hours if needed.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: Rectal: 0.2 mg/kg; maximum dose: 20 mg/dose; dose may be repeated in 4 to 12 hours if needed.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Weight-band dosing: </i>
<b>Note:</b> Dosing will provide between 90% and 180% of the calculated weight-based dose; safety has been established in clinical trials. Do not use more than 5 times per month or for more than 1 episode every 5 days.</p>
<p style="text-indent:-2em;margin-left:8em;">Children 2 to 5 years:</p>
<table border="1" frame="border" rules="all">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center" colspan="3">
<p style="text-indent:0em;">Weight-Band Dosage Recommendations for Rectal Diazepam: Children 2 to 5 Years</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Weight</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Dose (mg)</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Second Dose</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">6 to &lt;11 kg</p></td>
<td align="center">
<p style="text-indent:0em;">5 mg</p></td>
<td align="center">
<p style="text-indent:0em;">May repeat dose in 4 to 12 hours if needed.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">11 to &lt;16 kg</p></td>
<td align="center">
<p style="text-indent:0em;">7.5 mg</p></td>
<td align="center">
<p style="text-indent:0em;">May repeat dose in 4 to 12 hours if needed.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">16 to &lt;21 kg</p></td>
<td align="center">
<p style="text-indent:0em;">10 mg</p></td>
<td align="center">
<p style="text-indent:0em;">May repeat dose in 4 to 12 hours if needed.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">21 to &lt;26 kg</p></td>
<td align="center">
<p style="text-indent:0em;">12.5 mg</p></td>
<td align="center">
<p style="text-indent:0em;">May repeat dose in 4 to 12 hours if needed.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">26 to &lt;31 kg</p></td>
<td align="center">
<p style="text-indent:0em;">15 mg</p></td>
<td align="center">
<p style="text-indent:0em;">May repeat dose in 4 to 12 hours if needed.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">31 to &lt;36 kg</p></td>
<td align="center">
<p style="text-indent:0em;">17.5 mg</p></td>
<td align="center">
<p style="text-indent:0em;">May repeat dose in 4 to 12 hours if needed.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">36 to 44 kg</p></td>
<td align="center">
<p style="text-indent:0em;">20 mg</p></td>
<td align="center">
<p style="text-indent:0em;">May repeat dose in 4 to 12 hours if needed.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:8em;">Children 6 to 11 years:</p>
<table border="1" frame="border" rules="all">
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left" colspan="3">
<p style="text-indent:0em;">Weight-Band Dosage Recommendations for Rectal Diazepam: Children 6 to 11 Years</p></th></tr>
<tr>
<th align="left">
<p style="text-indent:0em;">Weight</p></th>
<th align="left">
<p style="text-indent:0em;">Dose (mg)</p></th>
<th align="left">
<p style="text-indent:0em;">Second Dose</p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">10 to &lt;17 kg</p></td>
<td align="left">
<p style="text-indent:0em;">5 mg</p></td>
<td align="left">
<p style="text-indent:0em;">May repeat dose in 4 to 12 hours if needed.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">17 to &lt;26 kg</p></td>
<td align="left">
<p style="text-indent:0em;">7.5 mg</p></td>
<td align="left">
<p style="text-indent:0em;">May repeat dose in 4 to 12 hours if needed.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">26 to &lt;34 kg</p></td>
<td align="left">
<p style="text-indent:0em;">10 mg</p></td>
<td align="left">
<p style="text-indent:0em;">May repeat dose in 4 to 12 hours if needed.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">34 to &lt;42 kg</p></td>
<td align="left">
<p style="text-indent:0em;">12.5 mg</p></td>
<td align="left">
<p style="text-indent:0em;">May repeat dose in 4 to 12 hours if needed.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">42 to &lt;51 kg</p></td>
<td align="left">
<p style="text-indent:0em;">15 mg</p></td>
<td align="left">
<p style="text-indent:0em;">May repeat dose in 4 to 12 hours if needed.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">51 to &lt;59 kg</p></td>
<td align="left">
<p style="text-indent:0em;">17.5 mg</p></td>
<td align="left">
<p style="text-indent:0em;">May repeat dose in 4 to 12 hours if needed.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">59 to 74 kg</p></td>
<td align="left">
<p style="text-indent:0em;">20 mg</p></td>
<td align="left">
<p style="text-indent:0em;">May repeat dose in 4 to 12 hours if needed.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents:</p>
<table border="1" frame="border" rules="all">
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left" colspan="3">
<p style="text-indent:0em;">Weight-Band Dosage Recommendations for Rectal Diazepam: Children ≥12 Years and Adolescents</p></th></tr>
<tr>
<th align="left">
<p style="text-indent:0em;">Weight</p></th>
<th align="left">
<p style="text-indent:0em;">Dose (mg)</p></th>
<th align="left">
<p style="text-indent:0em;">Second Dose</p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">14 to &lt;26 kg</p></td>
<td align="left">
<p style="text-indent:0em;">5 mg</p></td>
<td align="left">
<p style="text-indent:0em;">May repeat dose in 4 to 12 hours if needed.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">26 to &lt;38 kg</p></td>
<td align="left">
<p style="text-indent:0em;">7.5 mg</p></td>
<td align="left">
<p style="text-indent:0em;">May repeat dose in 4 to 12 hours if needed.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">38 to &lt;51 kg</p></td>
<td align="left">
<p style="text-indent:0em;">10 mg</p></td>
<td align="left">
<p style="text-indent:0em;">May repeat dose in 4 to 12 hours if needed.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">51 to &lt;63 kg</p></td>
<td align="left">
<p style="text-indent:0em;">12.5 mg</p></td>
<td align="left">
<p style="text-indent:0em;">May repeat dose in 4 to 12 hours if needed.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">63 to &lt;76 kg</p></td>
<td align="left">
<p style="text-indent:0em;">15 mg</p></td>
<td align="left">
<p style="text-indent:0em;">May repeat dose in 4 to 12 hours if needed.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">76 to &lt;88 kg</p></td>
<td align="left">
<p style="text-indent:0em;">17.5 mg</p></td>
<td align="left">
<p style="text-indent:0em;">May repeat dose in 4 to 12 hours if needed.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">88 to 111 kg</p></td>
<td align="left">
<p style="text-indent:0em;">20 mg</p></td>
<td align="left">
<p style="text-indent:0em;">May repeat dose in 4 to 12 hours if needed.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Rectal: Undiluted 5 mg/mL parenteral formulation (filter if using ampul): Infants, Children, and Adolescents: 0.5 mg/kg/dose then 0.25 mg/kg/dose in 10 minutes if needed. Maximum dose: 20 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gal.2007','lexi-content-ref-18245435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gal.2007','lexi-content-ref-18245435'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="98f720da-4e7e-4163-a85a-e8df3fee1f21">Status epilepticus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Status epilepticus:</b></p>
<p style="text-indent:-2em;margin-left:4em;">IV (preferred route):</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-directed: Infants &gt;30 days, Children, and Adolescents: IV: 0.15 to 0.2 mg/kg/dose slow IV; may repeat dose once in 5 minutes; maximum dose: 10 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26900382','lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26900382','lexi-content-ref-22528274'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Fixed dosing: Manufacturer's labeling:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants &gt;30 days and Children &lt;5 years: IV: 0.2 to 0.5 mg slow IV every 2 to 5 minutes up to a maximum total dose of 5 mg; repeat in 2 to 4 hours if needed.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥5 years and Adolescents: IV: 1 mg slow IV every 2 to 5 minutes up to a maximum of 10 mg; repeat in 2 to 4 hours if needed.</p>
<p style="text-indent:-2em;margin-left:4em;">Rectal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26900382','lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26900382','lexi-content-ref-22528274'])">Ref</a></span>): <b>Note:</b> For use when IV access unavailable.</p>
<p style="text-indent:-2em;margin-left:6em;">Children 2 to 5 years: Rectal: 0.5 mg/kg; maximum dose: 20 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Children 6 to 11 years: Rectal: 0.3 mg/kg; maximum dose: 20 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: Rectal: 0.2 mg/kg; maximum dose: 20 mg/dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="396e06c7-65c9-4188-951b-dc4f1231f5e6">Febrile seizure, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Febrile seizure, prophylaxis:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Although there is evidence that prophylaxis with diazepam may reduce recurrence of febrile seizures, use is not routinely recommended since risks of toxicity generally outweigh the benefits (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18519501']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18519501'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children: Oral: 1 mg/kg/day divided every 8 hours; initiate therapy at first sign of fever and continue for 24 hours after fever resolves (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8510706']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8510706'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cf826ffb-f5f2-4f36-bc1a-8bc5f4f7ed1f">Spasticity/muscle spasms</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Spasticity/muscle spasms: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>General dosing:</i>
<b>Note:</b> Initiate therapy with lowest dose; dose should be individualized and titrated to effect and tolerability:</p>
<p style="text-indent:-2em;margin-left:6em;">Fixed dosing: Infants ≥6 months, Children, and Adolescents: Oral: Initial: 1 to 2.5 mg 3 to 4 times daily; increase gradually as needed and tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-directed dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.2'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥6 months and Children &lt;12 years: Oral: 0.12 to 0.8 mg/kg/day in divided doses every 6 to 8 hours; maximum dose: 10 mg/dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: Oral: 2 to 10 mg 2 to 4 times daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cerebral palsy-associated spasticity:</i> Limited data available. <b>Note:</b> Dose should be individualized and titrated to effect and tolerability. Diazepam should be considered short-term treatment as there is insufficient evidence regarding motor function improvement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20101040']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20101040'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-directed dosing: Children: Oral: 0.01 to 0.3 mg/kg/day divided 2 <b>or</b> 4 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Fixed dosing: Children ≥5 years and Adolescents: Oral: Initial: 1 to 2 mg/dose 3 times daily; may titrate to response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-5339679','lexi-content-ref-5317889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-5339679','lexi-content-ref-5317889'])">Ref</a></span>). Doses up to 5 mg 4 times daily have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-5339679']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-5339679'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Low-dose fixed bedtime dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15840761']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15840761'])">Ref</a></span>): Children &lt;12 years: Oral:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;8.5 kg: 0.5 to 1 mg at bedtime.</p>
<p style="text-indent:-2em;margin-left:8em;">8.5 to 15 kg: 1 to 2 mg at bedtime.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tetanus-associated spasm: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Fixed dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>): <b>Note:</b> Respiratory support should be available during therapy.</p>
<p style="text-indent:-2em;margin-left:8em;">Infants &gt;30 days and children &lt;5 years: IV, IM: 1 to 2 mg every 3 to 4 hours as needed.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥5 years and Adolescents: IV, IM: 5 to 10 mg every 3 to 4 hours as needed.</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-directed dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.2'])">Ref</a></span>): Infants, Children, and Adolescents: IV: Initial: 0.1 to 0.2 mg/kg/dose every 2 to 6 hours; titrate as needed. <b>Note:</b> Initial recommended adult dose is 5 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Muscle spasm/spasticity associated with chronic/terminal illness (eg, palliative care settings):</i> Limited data available: Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: 0.12 to 0.8 mg/kg/day divided every 6 to 12 hours; maximum dose: 10 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17933619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17933619'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">IM, IV: 0.05 to 0.2 mg/kg/dose every 6 to 12 hours; maximum total dose: 0.6 mg/kg cumulative in 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17933619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17933619'])">Ref</a></span>); <b>Note:</b> In palliative situations, the usual initial dose for children &lt;5 years is 5 mg/dose and in children ≥5 years and adolescents is 10 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7fe66abc-d47c-49e2-97a2-40d3d672b968">Sedation, anxiolysis, and amnesia prior to procedure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sedation, anxiolysis, and amnesia prior to procedure:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥6 months: 0.2 to 0.3 mg/kg 45 to 60 minutes prior to procedure. Maximum dose: 10 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12142810','lexi-content-ref-2216645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12142810','lexi-content-ref-2216645'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children: 0.2 to 0.5 mg/kg 45 to 60 minutes prior to procedure; maximum dose: 10 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11973494','lexi-content-ref-3970333','lexi-content-ref-12142810','lexi-content-ref-23019837','lexi-content-ref-2216645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11973494','lexi-content-ref-3970333','lexi-content-ref-12142810','lexi-content-ref-23019837','lexi-content-ref-2216645'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: 0.2 to 0.3 mg/kg 45 to 60 minutes prior to procedure. Maximum dose: 10 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12142810','lexi-content-ref-2216645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12142810','lexi-content-ref-2216645'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IV:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: Initial: 0.05 to 0.1 mg/kg over 3 to 5 minutes, titrate slowly to effect (maximum total dose: 0.25 mg/kg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16517277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16517277'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: IV: 5 mg; may repeat with 2.5 mg if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2216645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2216645'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51109213"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Not dialyzable (0% to 5%); supplemental dose is not necessary.</p></div>
<div class="block dohp drugH1Div" id="F51109214"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution. The oral tablets are contraindicated in severe hepatic impairment.</p></div>
<div class="block adr drugH1Div" id="F158991"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions may vary by route of administration.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Drowsiness (23%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (≥1%), vasodilation (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (≥1%), diarrhea (4%), dysgeusia (3%), hiccups (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormality in thinking (≥1%), agitation (≥1%), ataxia (3%), confusion (≥1%), dizziness (3%), dysarthria (≥1%), emotional lability (≥1%), euphoria (3%), headache (5%), nervousness (≥1%), pain (≥1%), speech disturbance (≥1%), vertigo (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma (2%), epistaxis (2%), nasal discomfort (6%), rhinitis (≥1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, circulatory shock, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, pruritus, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, lymphadenopathy, neutropenia</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Tonic clonic type of status epilepticus</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Hyperkinetic muscle activity</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Mydriasis, nystagmus disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Increased cough</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: ECG changes, localized phlebitis, venous thrombosis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Change in libido</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Altered salivation, constipation, gastrointestinal distress, nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary incontinence, urinary retention</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Neutropenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase, increased serum transaminases, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anterograde amnesia, central nervous system depression, depression, drug abuse, drug dependence, drug withdrawal, fatigue, hypoactivity, lethargy, myasthenia, paradoxical central nervous system stimulation, psychiatric signs and symptoms, rebound anxiety, slurred speech</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, diplopia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Hypoventilation</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Miscellaneous: Paradoxical reaction</p></div>
<div class="block coi drugH1Div" id="F159009"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to diazepam or any component of the formulation; acute narrow-angle glaucoma.</p>
<p style="text-indent:-2em;margin-left:4em;">Injection: Additional contraindications: Untreated open-angle glaucoma.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Additional contraindications: Untreated open-angle glaucoma; use in infants &lt;6 months of age, myasthenia gravis, severe respiratory impairment, severe hepatic impairment, sleep apnea syndrome.</p></div>
<div class="block war drugH1Div" id="F158988"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anterograde amnesia: Benzodiazepines have been associated with anterograde amnesia (Nelson 1999).</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Paradoxical reactions: Paradoxical reactions, including hyperactive or aggressive behavior, have been reported with benzodiazepines; risk may be increased in adolescent/pediatric, geriatric patients, or patients with a history of alcohol use disorder or psychiatric/personality disorders (Mancuso 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">• Sleep-related activities: Hazardous sleep-related activities such as sleep-driving, cooking and eating food, and making phone calls while asleep have been noted with benzodiazepines (Dolder 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">• Suicidal ideation: Intranasal: Pooled analysis of trials involving various antiseizure medications (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% of treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials ≤24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify health care provider immediately if symptoms occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Convulsive disorders: When used as an adjunct in treating convulsive disorders, an increase in frequency/severity of tonic-clonic seizures may occur and require dose adjustment of antiseizure medication. Abrupt withdrawal may result in a temporary increase in the frequency and/or severity of seizures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Depression: Avoid use in patients with depression because of concerns about worsening mood symptoms, particularly if suicidal risk may be present, except for acute or emergency situations (eg, acute agitation, status epilepticus) (Craske 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Glaucoma: May be used in patients with open-angle glaucoma who are receiving appropriate therapy; contraindicated in acute narrow-angle glaucoma and untreated open-angle glaucoma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment. Oral tablet is contraindicated in patients with severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Reduce dose or avoid use in patients with respiratory disease, including chronic obstructive pulmonary disease or sleep apnea. Benzodiazepines may cause significant respiratory depression. Oral tablet is contraindicated in patients with severe respiratory impairment or sleep apnea syndrome.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Concomitant use with opioids:<b> [US Boxed Warning]: </b>
<b>Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death; reserve concomitant prescribing of these drugs for use in patients for whom </b>
<b>alternative treatment options are inadequate, and limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Debilitated patients: Use with caution; active metabolites with extended half-lives may lead to delayed accumulation and adverse effects; limit dose to smallest effective amount and increase gradually and as tolerated to avoid adverse reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult patients: Use with caution; active metabolites with extended half-lives may lead to delayed accumulation and adverse effects; limit dose to smallest effective amount and increase gradually and as tolerated to avoid adverse reactions. Older adults may be at an increased risk of death with use; risk has been found highest within the first 4 months of use in older adult dementia patients (Jennum 2015; Saarelainen 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Fall risk: Use with extreme caution in patients who are at risk of falls; benzodiazepines have been associated with falls and traumatic injury (Nelson 1999).</p>
<p style="text-indent:-2em;margin-left:4em;">• Obese patients: Use benzodiazepines with caution in obese patients; may have prolonged action when discontinued.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychotic patients: Use of diazepam is not recommended in place of appropriate therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol and/or sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol and/or benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Parenteral: Vesicant; ensure proper needle or catheter placement prior to and during administration; avoid extravasation. Acute hypotension, muscle weakness, apnea, and/or cardiac arrest have occurred with parenteral administration. Acute effects may be more prevalent in patients receiving concurrent barbiturates, opioids, or ethanol. Appropriate resuscitative equipment and qualified personnel should be available during administration and monitoring. Avoid use of the injection in patients in shock, coma, or in acute ethanol intoxication with depression of vital signs. Intra-arterial injection should be avoided. Tonic status epilepticus has been precipitated in patients treated with diazepam IV for absence status or absence variant status.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP ["Inactive" 1997]; Wilson 2000; Wilson 2005; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">• Rectal gel: Administration of rectal gel should only be performed by individuals trained to recognize characteristic seizure activity for which the product is indicated, and capable of monitoring response to determine need for additional medical intervention. Not recommended for chronic, daily use. Use with caution in patients with neurologic damage.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abuse, misuse, and substance use disorder: <b>[US Boxed Warning]:</b>
<b> The use of benzodiazepines, including diazepam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. </b>
<b>Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Assess each patient's risk for abuse, misuse, and addiction prior to and throughout treatment; </b>counsel patients at increased risk on proper use and monitoring for signs and symptoms of abuse, misuse, and substance use disorder. Institute early treatment or refer patients in whom substance use disorder is suspected. Limit dosages and durations to the minimum required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dependence and withdrawal reactions<b>: </b>
<b>[US Boxed Warning]: </b>
<b>The continued use of benzodiazepines, including diazepam, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of diazepam after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue diazepam or reduce the dosage. </b>Some patients may develop a protracted withdrawal syndrome lasting &gt;12 months; may be difficult to differentiate withdrawal symptoms from reemergence or continuation of symptoms for which benzodiazepines were prescribed. Flumazenil may cause withdrawal in patients receiving long-term benzodiazepine therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tolerance: Diazepam is a long half-life benzodiazepine. Duration of action after a single dose is determined by redistribution rather than metabolism. Tolerance develops to the sedative, hypnotic, and antiseizure effects. It does not develop to the anxiolytic or skeletal muscle relaxing effects (Vinkers 2012). Chronic use of this agent may increase the perioperative benzodiazepine dose needed to achieve desired effect.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878421"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Neonates and young infants have decreased metabolism of diazepam and desmethyldiazepam (active metabolite), both can accumulate with repeated use and cause increased toxicity.</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009). Diazepam Intensol Oral Solution (Concentration) contains 19% alcohol.</p></div>
<div class="block foc drugH1Div" id="F159001"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">diazePAM Intensol: 5 mg/mL (30 mL) [contains alcohol, usp; unflavored flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/mL (30 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, Rectal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diastat AcuDial: 10 mg (1 ea [DSC]); 20 mg (1 ea [DSC]) [contains alcohol, usp, benzoic acid, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diastat Pediatric: 2.5 mg (1 ea [DSC]) [contains benzoic acid, benzyl alcohol, propylene glycol, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg (1 ea); 10 mg (1 ea); 20 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Liquid, Nasal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Valtoco 10 MG Dose: 10 mg/0.1 mL (1 ea) [contains alcohol, usp]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Valtoco 5 MG Dose: 5 mg/0.1 mL (1 ea) [contains alcohol, usp]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Liquid Therapy Pack, Nasal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Valtoco 15 MG Dose: 2 devices, 7.5 mg/0.1 mL each (1 ea) [contains alcohol, usp]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Valtoco 20 MG Dose: 2 devices, 10 mg/0.1 mL each (1 ea) [contains alcohol, usp]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/mL (2 mL, 10 mL); 10 mg/2 mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/5 mL (5 mL, 473 mL, 500 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/2 mL (2 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Valium: 2 mg [DSC] [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Valium: 2 mg [scored; contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Valium: 5 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Valium: 5 mg [DSC] [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Valium: 5 mg [scored; contains corn starch, fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Valium: 10 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Valium: 10 mg [DSC] [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Valium: 10 mg [scored; contains corn starch, fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg, 5 mg, 10 mg</p></div>
<div class="block geq drugH1Div" id="F158984"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F159012"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Concentrate</b> (diazePAM Intensol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/mL (per mL): $1.43</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Concentrate</b> (diazePAM Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/mL (per mL): $5.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Diastat AcuDial Rectal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $420.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (diazePAM Rectal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $306.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $364.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $364.06</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Liquid</b> (Valtoco 10 MG Dose Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10MG/0.1ML (per each): $418.21</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Liquid</b> (Valtoco 5 MG Dose Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5MG/0.1ML (per each): $418.21</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Liquid Therapy Pack</b> (Valtoco 15 MG Dose Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5MG/0.1ML (per each): $418.21</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Liquid Therapy Pack</b> (Valtoco 20 MG Dose Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10MG/0.1ML (per each): $418.21</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (diazePAM Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/mL (per mL): $11.18 - $20.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (diazePAM Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $0.10 - $0.24</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.16 - $0.32</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.31 - $0.43</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Valium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $7.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $10.92</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $18.39</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866574"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, Rectal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diastat: 10 mg (2 mL) [contains alcohol, usp, benzoic acid, benzyl alcohol, propylene glycol, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL ([DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Valium: 5 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg, 5 mg, 10 mg</p></div>
<div class="block csi drugH1Div" id="F159082"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-IV</p></div>
<div class="block adm drugH1Div" id="F159006"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with food or water. Dilute or mix oral concentrate with water, juice, soda, applesauce, or pudding before use; measure dose only with calibrated dropper provided.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intranasal:</b> Do not test or prime before use. Administer one spray into one nostril. Some doses require an additional spray into the alternate nostril; refer to dosing for additional details. Do not administer a second dose if the patient is having trouble breathing or is excessively sedated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Administer (undiluted) deep into the muscle mass.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer undiluted by slow IV push; do not mix with other solutions or medications. Rapid injection may cause respiratory depression or hypotension. In adults, maximum infusion rate is 5 mg/minute. Do not administer through small veins (eg, dorsum of hand/wrist). Avoid intra-arterial administration. Continuous infusion is not recommended because of precipitation in IV fluids and absorption of drug into infusion bags and tubing.</p>
<p style="text-indent:-2em;margin-left:4em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extravasation management:</b> If extravasation occurs, stop IV administration immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Apply dry cold or warm compresses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15192356','lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15192356','lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rectal gel:</b> Prior to administration, confirm that prescribed dose is visible and correct and that the green "ready" band is visible. Place patient on side (facing person responsible for monitoring), with top leg bent forward. Insert rectal tip (lubricated) gently into rectum until rim fits snugly against rectal opening; push plunger gently over 3 seconds. After additional 3 seconds, remove syringe; hold buttocks together while slowly counting to 3 to prevent leakage; keep patient on side, facing towards you, and continue to observe patient; discard any unused medication, syringe, and all used materials; do not reuse; see manufacturer's Administration and Disposal Instructions. May consider use of parenteral formulation rectally if gel not available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1547766']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1547766'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52612536"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Intranasal: Device comes ready to use; do not test or prime device before use. Each device delivers 1 spray only. Administer 1 spray into 1 nostril from a single device. If a second device is needed for the full dose, administer the second spray in the alternate nostril from a new device. A second dose should not be administered if the patient is having trouble breathing or excessive sedation.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with food or water.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral concentrate solution (5 mg/mL): Dilute or mix product with water, juice (except grapefruit juice), soda, applesauce, or pudding before use. Measure dose only with calibrated dropper provided.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Administer undiluted (5 mg/mL) deep into muscle mass.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Administer undiluted (5 mg/mL) direct IV; do not mix with other solutions or medications. Rapid injection may cause respiratory depression or hypotension; infants and children: Do not exceed 1 to 2 mg/minute IV push; adults: 5 mg/minute. Continuous infusion is not recommended because of precipitation in IV fluids and absorption of drug into infusion bags and tubing.</p>
<p style="text-indent:-2em;margin-left:6em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop IV administration immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; elevate extremity. Apply dry cold compresses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15192356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15192356'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Rectal: Diastat AcuDial: Prescribed dose must be "dialed in" and locked before dispensing; consult package insert for directions on setting prescribed dose. Prior to administration, confirm that the prescribed dose is visible and correct and that the green "ready" band is visible.</p>
<p style="text-indent:-2em;margin-left:4em;">Diastat AcuDial and Diastat: Place patient on side (facing person responsible for monitoring), with top leg bent forward. Insert rectal tip (lubricated) gently into rectum until rim fits snug against rectal opening; push plunger gently over 3 seconds. After additional 3 seconds, remove syringe; hold buttocks together while slowly counting to 3 to prevent leakage; keep patient on side, facing towards you and continue to observe patient; discard any unused medication, syringe, and all used materials safely away from children; do not reuse; see Administration and Disposal Instructions that come with product.</p></div>
<div class="block meg drugH1Div" id="F49627710"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Valium: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F013263Orig1s100lbl.pdf%23page%3D19&amp;token=1y9DgwwuX64D8kJqpO9ZO7jnvBYNEso6mKJqjcqpKmV0glw2Q5N0%2FYtwEHKsSkksPqLI54Mt6%2BL7k4TO933PC2DGqw9%2Fncqg2LolHmxWqZO4FZxUXUsTCBx4xbm8ajxn&amp;TOPIC_ID=9345" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/013263Orig1s100lbl.pdf#page=19</a></p>
<p style="text-indent:-2em;margin-left:4em;">Valtoco nasal spray: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F211635s008lbl.pdf%23page%3D24&amp;token=2qffI8ZgjU4DxO8lxasHwTT1YPPrP9DI26hfA5jgkE5DzknIMT4JUoFDfG%2FDm0aGd5WBusw7IHzqgzKpxMOLmKtifQmZTIlfEfUCvhibkzkNvo%2Bsf5ZFNYVMwfp9Urzp&amp;TOPIC_ID=9345" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211635s008lbl.pdf#page=24</a></p></div>
<div class="block use drugH1Div" id="F159005"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Alcohol withdrawal syndrome (oral and injection):</b> Symptomatic relief of acute agitation, tremor, impending or acute delirium, delirium tremens, and hallucinosis associated with alcohol withdrawal.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Anxiety, acute/severe (oral and injection): </b>Short-term relief of severe anxiety symptoms.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Anxiety disorders (oral and injection):</b> Management of anxiety disorders.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Muscle spasm, spasticity, and/or rigidity (oral and injection):</b> As an adjunct for the relief of skeletal muscle spasm due to reflex spasm caused by local pathology (eg, inflammation of muscles or joints, secondary to trauma); spasticity caused by upper motor neuron disorders (eg, cerebral palsy, paraplegia); athetosis; stiff-man syndrome; and tetanus.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Procedural anxiety, premedication (injection):</b> Relief of anxiety and tension in patients undergoing surgical procedures; prior to cardioversion for the relief of anxiety and tension and to diminish patient's recall (IV only); as an adjunct prior to endoscopic procedures for apprehension, anxiety, or acute stress reactions and to diminish patient's recall.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Use of diazepam in patients undergoing cardioversion or endoscopic procedures has been superseded by agents with a more pharmacokinetically favorable profile (eg, midazolam) (Thomas 2014; Triantafillidis 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures, acute, active:</b> Adjunct in convulsive disorders (oral); treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy (≥6 years of age [intranasal], ≥2 years of age [rectal]); adjunct in severe recurrent convulsive seizures (injection).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Status epilepticus (injection):</b> Adjunct in status epilepticus.</p></div>
<div class="block off-label drugH1Div" id="F25725525"><span class="drugH1">Use: Off-Label: Adult</span><p>Hydroxychloroquine/chloroquine toxicity (severe); Intoxication (cocaine, methamphetamine, and other sympathomimetics); Neuroleptic malignant syndrome; Opioid withdrawal (autonomic instability and agitation); Serotonin syndrome (serotonin toxicity); Vertigo, acute episodes</p></div>
<div class="block mst drugH1Div" id="F159090"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">DiazePAM may be confused with diazoxide, dilTIAZem, Ditropan, LORazepam</p>
<p style="text-indent:-2em;margin-left:4em;">Valium may be confused with Valcyte</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Diazepam is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older due to risk of abuse, misuse, physical dependence, and addiction. In addition, older adults have an increased risk of impaired cognition, delirium, falls, fractures, and motor vehicle accidents with benzodiazepine use, and slower metabolism of long-acting benzodiazepines (eg, diazepam). However, benzodiazepines may be appropriate in the elderly when used for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine or ethanol withdrawal, severe generalized anxiety disorder, or periprocedural anesthesia (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F159074"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2B6 (minor), CYP2C19 (major), CYP2C9 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F158993"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: DiazePAM may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine. Monitor for respiratory depression, hypotension, and other toxicities if these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cosyntropin: May enhance the hepatotoxic effect of DiazePAM.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inducers (Moderate): May decrease the serum concentration of DiazePAM.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inhibitors (Moderate): May increase the serum concentration of DiazePAM.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inhibitors (Strong): May increase the serum concentration of DiazePAM.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of DiazePAM.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of DiazePAM.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of DiazePAM.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of DiazePAM.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disulfiram: May enhance the adverse/toxic effect of Products Containing Ethanol. Management: Do not use disulfiram with dosage forms that contain ethanol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: May decrease the serum concentration of DiazePAM. DiazePAM may increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ilaprazole: May increase the serum concentration of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: May enhance the sedative effect of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: Benzodiazepines may enhance the CNS depressant effect of Methadone.  Management: Clinicians should generally avoid concurrent use of methadone and benzodiazepines when possible; any combined use should be undertaken with extra caution.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: Products Containing Ethanol may enhance the adverse/toxic effect of Methotrimeprazine. Specifically, a disulfiram-like reaction may occur and CNS depressant effects may be increased.  Management: Avoid products containing alcohol in patients treated with methotrimeprazine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of DiazePAM. Metoclopramide may increase the serum concentration of DiazePAM.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetroNIDAZOLE (Systemic): May enhance the adverse/toxic effect of Products Containing Propylene Glycol. A disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of DiazePAM. Nirmatrelvir and Ritonavir may decrease the serum concentration of DiazePAM.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: Benzodiazepines may enhance the adverse/toxic effect of OLANZapine.  Management: Monitor closely for hypotension, respiratory or central nervous system depression, and bradycardia if olanzapine is combined with benzodiazepines. Use of parenteral benzodiazepines with IM olanzapine is not recommended.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ombitasvir, Paritaprevir, and Ritonavir: May decrease serum concentrations of the active metabolite(s) of DiazePAM. Ombitasvir, Paritaprevir, and Ritonavir may decrease the serum concentration of DiazePAM.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: May decrease serum concentrations of the active metabolite(s) of DiazePAM. Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir may decrease the serum concentration of DiazePAM.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ornidazole: May enhance the adverse/toxic effect of Products Containing Ethanol. Specifically, a disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ornidazole: May enhance the adverse/toxic effect of Products Containing Propylene Glycol. Specifically, a disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: Benzodiazepines may enhance the CNS depressant effect of Oxybate Salt Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May increase the serum concentration of DiazePAM. Ritonavir may decrease the serum concentration of DiazePAM.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secnidazole: Products Containing Ethanol may enhance the adverse/toxic effect of Secnidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secnidazole: Products Containing Propylene Glycol may enhance the adverse/toxic effect of Secnidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teduglutide: May increase the serum concentration of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F58004311"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use. Pregnancy testing is recommended before treating acute alcohol withdrawal symptoms (ASAM 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Therapy for anxiety should be individualized (BAP [McAllister-Williams 2017]); avoid the use of benzodiazepines for the treatment of anxiety disorders in patients planning to become pregnant (Larsen 2015).</p></div>
<div class="block pri drugH1Div" id="F159013"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Diazepam and its metabolites (N-desmethyldiazepam, temazepam, and oxazepam) cross the placenta (Kanto 1982; McElhatton 1994).</p>
<p style="text-indent:0em;margin-top:2em;">In-utero exposure to benzodiazepines has the potential to cause harm to the fetus. Teratogenic effects have been observed in some studies; however, a clear association has not been reported and additional data are needed (Bellantuono 2013; Freeman 2018; Grigoriadis 2019; Noh 2022; Szpunar 2022; Tinker 2019; Wikner 2007). Exposure to a benzodiazepine late in pregnancy may cause neonatal sedation (hypotonia, lethargy, respiratory depression) and/or symptoms of neonatal withdrawal (feeding difficulties, hyperreflexia, inconsolable crying, irritability, restlessness, tremors). Data related to long-term effects on neurodevelopment are inconclusive (Chen 2022; Radojčić 2017; Sundbakk 2022; Wang 2022). Newborns exposed to diazepam in utero should be monitored for feeding problems, respiratory depression, sedation, and withdrawal.</p>
<p style="text-indent:0em;margin-top:2em;">Treatment for alcohol withdrawal may be considered for pregnant patients with at least moderate symptoms (CIWA-Ar scores ≥10) (ASAM 2020). The short-term use of a long-acting benzodiazepine may be used in pregnant patients requiring treatment of acute alcohol withdrawal symptoms (WHO 2014); however, the use of shorter-acting benzodiazepines is preferred in patients at risk for preterm delivery or when treatment is needed during the third trimester (ASAM 2020). Although recommendations vary by guideline, the use of diazepam may be considered when treating pregnant patients (BAP [McAllister-Williams 2017]; SOGC [Graves 2020]; WFSBP/IAWMH [Thibaut 2019]). Monitor newborns for fetal alcohol spectrum disorders in addition to benzodiazepine intoxication (ASAM 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Therapy for anxiety during pregnancy should be individualized. Untreated or inadequately treated psychiatric illness may lead to poor adherence to prenatal care and adverse pregnancy outcomes (ACOG 2008). Benzodiazepines are not preferred when pharmacologic treatment for anxiety disorders is needed during pregnancy (BAP [McAllister-Williams 2017]; Larsen 2015); however, if a benzodiazepine is needed, diazepam may be considered for the treatment of anxiety in pregnant patients (based on the trimester of exposure). If possible, avoid scheduled doses of benzodiazepines in the month prior to delivery to reduce the risk of withdrawal symptoms in the newborn (Larsen 2015).</p>
<p style="text-indent:0em;margin-top:2em;">When treating pregnant patients for seizure disorders, monotherapy with the lowest effective dose and avoidance of medications known to have a high incidence of teratogenic effects is recommended (Harden 2009; Wlodarczyk 2012).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to diazepam is ongoing. Health care providers are encouraged to enroll patients exposed to diazepam during pregnancy in the National Pregnancy Registry for Psychiatric Medications (866-961-2388) or the North American Antiepileptic Drug (NAAED) Pregnancy Registry (888-233-2334).</p></div>
<div class="block brc drugH1Div" id="F159014"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Diazepam and its metabolites are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of diazepam in breast milk are available:</p>
<p style="text-indent:-2em;margin-left:4em;">• The presence of diazepam was evaluated in 4 patients who received diazepam 20 mg IV prior to delivery, then diazepam 10 mg orally once daily from days 3 to 6 postpartum. Breast milk was sampled ~9 and ~23 hours after the oral doses. Diazepam and methyldiazepam were present in breast milk in concentrations ranging from 12 to 43 ng/mL and 12 to 85 ng/mL, respectively (Brandt 1976).</p>
<p style="text-indent:-2em;margin-left:4em;">• Breast milk and infant serum were sampled following administration of diazepam 10 mg 3 times daily to 3 mothers for 6 days after delivery. Diazepam breast milk concentrations were 51 ng/mL (4 days postpartum) and 78 ng/mL (6 days postpartum). Methyldiazepam breast milk concentrations were 28 ng/mL (4 days postpartum) and 52 ng/mL (6 days postpartum). Diazepam and methyldiazepam were present in the breastfed infant plasma (Erkkola 1972).</p>
<p style="text-indent:-2em;margin-left:4em;">• Additional studies have confirmed the presence of diazepam and methyldiazepam in breast milk; however, the maternal doses associated with reported breast milk concentrations were not clearly stated (Cole 1975; Dusci 1990; Wesson 1985).</p>
<p style="text-indent:-2em;margin-left:4em;">• The oxazepam metabolite has been detected in the urine of an infant exposed to diazepam via breast milk (Patrick 1972).</p>
<p style="text-indent:-2em;margin-left:4em;">• Relative infant doses (RID) of up to 11% have been reported for diazepam and methyldiazepam (McElhatton 1994). In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000); however, some sources note breastfeeding should only be considered if the RID is &lt;5% for psychotropic agents (Larsen 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">Drowsiness, lethargy, or weight loss in breastfed infants have been observed in case reports following maternal use of some benzodiazepines (Iqbal 2002), including diazepam (Patrick 1972; Wesson 1985).</p>
<p style="text-indent:-2em;margin-left:2em;">Diazepam has a long half-life that varies by age and is longer in preterm infants and full-term newborns, likely due to incomplete maturation of the metabolic pathway. Diazepam may accumulate in the breastfed infant, especially preterm infants or those exposed to chronic maternal doses (Davanzo 2013). Significant accumulation may occur even if the maternal dose is low (Wesson 1985).</p>
<p style="text-indent:-2em;margin-left:2em;">Breastfeeding during benzodiazepine therapy is not recommended due to the potential for drowsiness in the breastfed infant (Larsen 2015); breastfeeding during diazepam therapy is not recommended by the manufacturer. A single maternal dose of diazepam may be compatible with breastfeeding (WHO 2002). If chronic use of a benzodiazepine is needed, use of shorter-acting agents is preferred in patients who are breastfeeding, and infants should be monitored (Davanzo 2013; WHO 2002).</p></div>
<div class="block mop drugH1Div" id="F158998"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Heart rate, respiratory rate, blood pressure, and mental status; liver enzymes and CBC with long-term therapy; clinical signs of propylene glycol toxicity (for continuous high-dose and/or long duration intravenous use) including serum creatinine, BUN, serum lactate, osmol gap. <b>Note:</b> An osmol gap of ≥10 was predictive of elevated propylene glycol concentrations; values of ≥12 suggest propylene glycol toxicity (Arroliga 2004; Barnes 2006; Yahwak 2008).</p></div>
<div class="block pha drugH1Div" id="F158987"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Long-acting benzodiazepine. Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the central nervous system, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization. Benzodiazepine receptors and effects appear to be linked to the GABA-A receptors. Benzodiazepines do not bind to GABA-B receptors.</p></div>
<div class="block phk drugH1Div" id="F159008"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Sedation: Pediatric patients: IV: 4 to 5 minutes (Krauss 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">Status epilepticus: IV: 1 to 3 minutes; Rectal: 2 to 10 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Classified as a long-acting benzodiazepine; classification based on benzodiazepines with half-life &gt;40 hours (Griffin 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">Indication-specific durations:</p>
<p style="text-indent:-2em;margin-left:6em;">Sedation: Pediatric patients: IV: 60 to 120 minutes (Krauss 2006).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Well absorbed (&gt;90%); delayed and decreased when administered with a moderate fat meal.</p>
<p style="text-indent:-2em;margin-left:4em;">Rectal: Well absorbed.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Intranasal: 0.8 to 1 L/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: 1.2 L/kg (range: 0.6 to 2 L/kg) (Greenblatt 1989a).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: 1.1 L/kg (range: 0.6 to 1.8 L/kg (Greenblatt 1989b).</p>
<p style="text-indent:-2em;margin-left:4em;">Rectal: 1 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding:</p>
<p style="text-indent:-2em;margin-left:4em;">Intranasal: 95% to 98%.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Neonates: 84% to 86% (Milsap 1994; Morselli 1980); Adults: 98%.</p>
<p style="text-indent:-2em;margin-left:4em;">Rectal: 95% to 98%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; diazepam is N-demethylated by CYP3A4 and 2C19 to the active metabolite N-desmethyldiazepam, and is hydroxylated by CYP3A4 to the active metabolite temazepam. N-desmethyldiazepam and temazepam are both further metabolized to oxazepam. Temazepam and oxazepam are largely eliminated by glucuronidation.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: &gt;90% (Lamson 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">Intranasal: 97%.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: &gt;90%.</p>
<p style="text-indent:-2em;margin-left:4em;">Rectal: 90%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: <b>Note:</b> Diazepam accumulates upon multiple dosing and the terminal elimination half-life is slightly prolonged.</p>
<p style="text-indent:-2em;margin-left:4em;">IM:</p>
<p style="text-indent:-2em;margin-left:6em;">Premature neonates (GA: 28 to 34 weeks): 54 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants: ~30 hours (Morselli 1973).</p>
<p style="text-indent:-2em;margin-left:6em;">Children 3 to 8 years: 18 hours (Morselli 1973).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: Parent: ~60 to 72 hours; Desmethyldiazepam: ~152 to 174 hours (Lamson 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">Intranasal: ~49 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Parent: 33 to 45 hours; Desmethyldiazepam: 87 hours (Cloyd 1998; Greenblatt 1989a).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Parent: 44 to 48 hours; Desmethyldiazepam: 100 hours (Greenblatt 1989b).</p>
<p style="text-indent:-2em;margin-left:4em;">Rectal: Parent: 45 to 46 hours; Desmethyldiazepam: 71 to 99 hours (Cloyd 1998).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Median: 1 hour (range: 0.25 to 2 hours) (Lamson 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">Intranasal: ~1.5 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: ~1 minute (Cloyd 1998).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: 15 minutes to 2.5 hours (1.25 hours when fasting; 2.5 hours with food) (Greenblatt 1989b).</p>
<p style="text-indent:-2em;margin-left:4em;">Rectal: 1.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (predominantly as glucuronide conjugates).</p></div>
<div class="block phksp drugH1Div" id="F51221003"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: In mild and moderate cirrhosis, the average half-life increases 2- to 5-fold, with individual half-lives over 500 hours reported. There is also an increase in volume of distribution, and average clearance decreases by almost half. Half-life is also prolonged with hepatic fibrosis to 90 hours (range: 66 to 104 hours), with chronic active hepatitis to 60 hours (range: 26 to 76 hours), and with acute viral hepatitis to 74 hours (range: 49 to 129 hours). In chronic active hepatitis, clearance is decreased by almost half.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: The half-life is increased by approximately 1 hour for each year of age beginning with a half-life of 20 hours at 20 years of age, as the volume of distribution is increased, and clearance is decreased. Consequently, there may be lower peak concentrations, higher trough concentration with multiple doses, and it may take longer to reach steady state.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F159015"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo diazepam | Diazepan | Stesolid | Valium</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Corticosan | Cuadel | Dezepan | Diactal | Diazepam ingram | Diazepam Lan | Diazepam lepret | Diazepam medifarma | Diazepam medipharma | Diazepam northia | Diazepam Puntanos | Diazepan biocrom | Diazepan bouzen | Diazepan fabop | Diazepan fabra | Diazepan vannier | Dipezona | Dipezona plus | Fabotranil | Glutasedan | Lembrol | Plidan | Psiconor | Psicotop | Saromet | Somasedan | Valium | Valtoco</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Gewacalm | Psychopax | Umbrium | Valium</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Antenex | Apo diazepam | Apx diazepam | Diazepam arx | Diazepam dp | Diazepam Ga | Diazepam str | Ducene | Noumed diazepam | Ranzepam | Valium | Valpam</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Azepam | D pam | Diason | Diazimet | Dipam | Easium | Evalin | Fizepam | Relaxen | Rozam | Sedapen | Sedex | Sedil | Sedium | Sedulin | Seduxen | Selium | Strenil | Sudex | Therapam | Tranquil</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Diazepam eurogenerics | Diazepam ratiopharm | Diazepam teva generics belgium | Diazetop | Valium</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Dizepin | Relanium | Valium</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Calmociteno | Compaz | Diazefast | Diazepam nq | Diazepan | Diazepan nq | Dienpax | Dienzepax | Furp diazepam | Kiatrium | Lfm diazepam | Menostress | Noan | Oxatrat | Relapax | Santiazepam | Somaplus | Uni diazepax | Valium | Valix</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Diazepam desitin | Diazepam mepha | Paceum | Stesolid | Valium</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Bamyl | Compaz | Elongal | Pacinax | Valium</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Clafer | Diazepan | Distensar | Valium</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo diazepam | Diazepam biotika | Diazepam desitin | Diazepam stada</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Diazep | Diazep CT | Diazepam stada | Faustan | Lamra | Neurolytril | Tranquase | Valium</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Calmaven | Diazepan | Diazex | Distenol | Valium | Vatran | Vaxepan</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Ansan | Consilium | Diazepam Apo | Diazepam Ecar | Dipaz | Valium</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Apaurin | Diapaks | Diazepam desitin | Diazepam ratiopharm | Diazepex | Faustan | Relium | Seduxen | Singlepen d | Valium</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Calium | Epival | Farcozepam | Neuril | Stesolid | Valinil | Valpam</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Diaceplex | Diazepam apotex | Diazepam bluefish | Diazepam cinfa | Diazepam durban | Diazepam normogen | Diazepam qualigen | Diazepam stada | Diazepam vir | Diazepan normon | Diazepan prodes | Drenian | Valium</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Apozepam | Diapam | Diazal | Medipam | Sedipam | Stesolid | Tensopam | Valium</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Diazepam accord | Diazepam arrow | Diazepam Merckle | Diazepam ratiopharm | Novazam | Valium</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Alupram | Atensine | Dialar | Diazemuls | Diazepam almus | Diazepam arrow | Diazepam astec | Diazepam berk | Diazepam cox | Diazepam kent | Diazepam sandoz | Evacalm | Rimapam | Sedapam | Stesolid | Tensium | Valium</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Apollonset | Atarviton | Stedon</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Kratium | Sedapam | Syn diazepam | Synium | Valencia | Valium</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Apaurin | Diazepam Alkaloid | Diazepam jadran | Diazepan Jadran | Normabel</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Seduxen | Valium</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Decazepam | Diazepin | Lovium | Mentalium | Paralium | Prozepam | Sakazepam | Stesolid | Trankinon | Valdimex | Validex | Valinter | Valisanbe | Valium</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Anxicalm | Diazemuls | Valium</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Assival | Disopam</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alvopam | Anxol | Calmpose | Daize | Dekopam | Diacalm | Diaze | Dipax | Direc | Dizep | Elpam | Equimood | Lakpam | Medipam | Neo mesmar | Paci quil | Paxum | Peacin | Placidox | Quietal | Repam | Valium | Zecalm | Zepase | Zepose | Zycalm</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Diapam | Diazedain | Diazepam mdi | Dij valom | Valiapam | Valiupam | Valum j</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ansiolin | Diazepam stada | Diazepam vm | Micropam | Noan | Valium | Vatran</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Remedium | Stedon | Stesolid | Valium</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Amel mita | Cellkam | Cercine | Condition | Curasina | Diapax | Diazepam amel | Diazepam fujimoto | Diazepam mita | Diazepam sawai | Diazepam towa | Euphorin | Gihitan | Horizon | Pealkit | Reliezen | Reliver | Renborin | Sedaril | Serenamin | Serenzin | Sonacon</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Biozepam | Calm | Cozepam | Da zepam | Valium</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Diazepam daewon | Melode | Myungin diazepam | Samjin Diazepam | Unizepam | Valium | Valuzepam</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Valium</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Diazepan | Stesolid | Valium</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Apaurin | Apo diazepam | Diapax | Diazepam d | Diazepex | Faustan | Relanium | Relium | Seduxen | Sibazon | Valium</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Valium</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Apaurin | Apo diazepam | Diapax | Diazep | Diazepam desitin | Diazepex | Diazer | Faustan | Relanium | Relium | Seduxen | Sibazon | Valium</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Apo diazepam | Valium</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Alboral | Freudal | Ifafonal | Nercon | Ortopsique | Rayne | Relazepam | Valium</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo diazepam | Calmpose | Diapine | Diapo | Dzp | Idaman pharma diazepam | Stesolid | Valium</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Ex5 diazepam | Unival | Valinex | Vincopam</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Diazepam accord | Diazepam alpharma | Diazepam flx | Diazepam Katwijk | Diazepam sandoz | Diazepamum | Stesolid | Valium</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Diazepam accord | Stesolid | Valium | Vival</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">D pam | Noumed diazepam | Propam | Stesolid</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Apo-diazepan | Pacitran | Reposepam | Valium | Vazen</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Anxionil | Pamizep | Trazepam | Tremodil | Ul diazepam | Valium | Valzep</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Anglopam | Anxosal | Apaurin | Arzepam | Cerelium | D mad | Delica | Depam | Diazip | Dizep | Kozypam | Neopam | Relax | Relaxipam | Rorpam | Tdpam | Valium</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Diazepam genoptim | Faustan | Neorelium | Relanium | Stesolid | Valium</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Diastat | Diastat acudial | Valium | Valtoco</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Bialzepam | Diazepam Pharmakern | Diazepam ratiopharm | Diazepam wynn | Metamidol | Unisedil | Valium</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Aneurol | Ansedan | Diazepan prodes | Lembrol | Psicozepam | Rolasedan | Valium</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Diazem | Epival (Diazepam) | Stesolid | Valium | Verzepam</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Diazepam desitin | Diazepam laropharm | Diazepam richter | Diazepam terapia | Valium</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Apaurin | Apo diazepam | Diapam | Diazepam desitin | Diazepex | Relanium | Relium | Seduxen | Sibazon | Sibazon ferein | Valium</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Stesolid | Valium</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Apozepam | Diazemuls novum | Diazepam accord | Diazepam bbs | Diazepam Nordic | Diazepam pilum | Stesolid | Stesolid novum | Valium</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo diazepam | Diapine | Diapo | Stesolid</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Apaurin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Diazepam desitin | Diazepam grindeks | Diazepam slovakofarma</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">A Zerax | Ammipam | Diadon | Diamed | Diano | Diapam | Diapine | Diaz | Diaza | Dinazep | Dipam | Divopan | Dizan | Dizep | Dizepam | Dopam | Dzp | Manodiazo | Manolium | Maya | Popam | Relanium | Ropam | Seduxen | Sipam | Stesolid | Tranolan | V day zepam | Valax | Valenium | Valium | Vapam | Vason | Zam | Zepam | Zopam</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Remedium | Valium</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Anksiyolin | Diapam | Diazem | Nervium | Zepam</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Anlin | Azepin | Balidium | Baogin | Bayu | Colsin | Comfort | Cozepam | Dean | Derginpin | Dialium | Dianlin | Dianzem | Diapin | Diapine | Diazejin | Diazelium | Dizepam | Dupin | Editin | Ginbo | Hua Pam | Jinlun | Jinpinfan | Neo Zine | Recin | Relax | Sedonin | Sonacon | Soudipan | Stesolid | Sulin | Talium | Tening | Thinin | Toufong | Tranzepam | Valisin | Valium | Vancolin | Vanconin | Vandrin | Walin | Wingent | Winii</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Apaurin | Diapam | Diazepam Apo | Relanium | Relium | Seduxen | Sibazon | Sibazone</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Cozepam | Solina</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Diazepam icu vita | Diazepam Sanderson | Diazepan | Glorius | Quiatril | Sincronex | Val | Valium</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Diazepan | Talema</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Benzopin | Betapam | Dynapam | Pax | Rolab-diazepam | Valium</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Dizam</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Dizam</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Abrams.1">
<a name="Abrams.1"></a>Abrams GM, Wakasa M. Chronic complications of spinal cord injury and disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 21, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319. doi: 10.1067/mpd.2001.116281.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28800805">
<a name="28800805"></a>Akerele E, Olupona T. Drugs of abuse. <i>Psychiatr Clin North Am</i>. 2017;40(3):501-517. doi: 10.1016/j.psc.2017.05.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/28800805/pubmed" id="28800805" target="_blank">28800805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17142550">
<a name="17142550"></a>American Academy of Pediatrics; American Academy of Pediatric Dentistry, Coté CJ, Wilson S; Work Group on Sedation. Guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures: an update. <i>Pediatrics</i>. 2006;118(6):2587-2602. doi: 10.1542/peds.2006-2780.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/17142550/pubmed" id="17142550" target="_blank">17142550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18378767">
<a name="18378767"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin No. 92: Use of psychiatric medications during pregnancy and lactation. <i>Obstet Gynecol.</i> 2008;111(4):1001-1020. doi:10.1097/AOG.0b013e31816fd910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/18378767/pubmed" id="18378767" target="_blank">18378767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32511109">
<a name="32511109"></a>American Society of Addiction Medicine (ASAM). The ASAM clinical practice guideline on alcohol withdrawal management. <i>J Addict Med</i>. 2020:14(3S)(suppl 1):1-72. doi:10.1097/ADM.0000000000000668<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/32511109/pubmed" id="32511109" target="_blank">32511109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Arnold.1">
<a name="Arnold.1"></a>Arnold TC, Ryan ML. Acute amphetamine and synthetic cathinone ("bath salt") intoxication. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 29, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15286548">
<a name="15286548"></a>Arroliga AC, Shehab N, McCarthy K, Gonzales JP. Relationship of continuous infusion lorazepam to serum propylene glycol concentration in critically ill adults. <i>Crit Care Med</i>. 2004;32(8):1709-1714.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/15286548/pubmed" id="15286548" target="_blank">15286548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35900161">
<a name="35900161"></a>Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part I: anxiety disorders. <i>World J Biol Psychiatry</i>. 2023;24(2):79-117. doi:10.1080/15622975.2022.2086295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/35900161/pubmed" id="35900161" target="_blank">35900161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16422667">
<a name="16422667"></a>Barnes BJ, Gerst C, Smith JR, Terrell AR, Mullins ME. Osmol gap as a surrogate marker for serum propylene glycol concentrations in patients receiving lorazepam for sedation. <i>Pharmacotherapy</i>. 2006;26(1):23-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/16422667/pubmed" id="16422667" target="_blank">16422667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Barry.2019">
<a name="Barry.2019"></a>Barry JD. Antimalarials. In: Nelson LS, Howland M, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS, eds. <i>Goldfrank's Toxicologic Emergencies</i>. 11th ed. New York, NY: McGraw-Hill; 2019:836-849.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32267799">
<a name="32267799"></a>Basura GJ, Adams ME, Monfared A, et al. Clinical practice guideline: Ménière's disease. <i>Otolaryngol Head Neck Surg</i>. 2020;162(suppl 2):S1-S55. doi:10.1177/0194599820909438<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/32267799/pubmed" id="32267799" target="_blank">32267799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23044244">
<a name="23044244"></a>Bellantuono C, Tofani S, Di Sciascio G, Santone G. Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. <i>Gen Hosp Psychiatry</i>. 2013;35(1):3-8. doi:10.1016/j.genhosppsych.2012.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/23044244/pubmed" id="23044244" target="_blank">23044244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28248609">
<a name="28248609"></a>Bhattacharyya N, Gubbels SP, Schwartz SR, et al. Clinical practice guideline: Benign paroxysmal positional vertigo (update). <i>Otolaryngol Head Neck Surg</i>. 2017;156(3)(suppl):S1-S47. doi: 10.1177/0194599816689667.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/28248609/pubmed" id="28248609" target="_blank">28248609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Boyer.2019">
<a name="Boyer.2019"></a>Boyer EW. Serotonin syndrome (serotonin toxicity). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 7, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Boyer.1">
<a name="Boyer.1"></a>Boyer EW, Seifert SA, Hernon C. Methamphetamine: Acute intoxication. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 16, 2019b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-989345">
<a name="989345"></a>Brandt R. Passage of diazepam and desmethyldiazepam into breast milk. <i>Arzneimittelforschung</i>. 1976;26(3):454-457.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/989345/pubmed" id="989345" target="_blank">989345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22528274">
<a name="22528274"></a>Brophy GM, Bell R, Claassen J, et al; Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. <i>Neurocrit Care</i>. 2012;17(1):3-23. doi: 10.1007/s12028-012-9695-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/22528274/pubmed" id="22528274" target="_blank">22528274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control and Prevention (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36413366">
<a name="36413366"></a>Chen VC, Wu SI, Lin CF, Lu ML, Chen YL, Stewart R. Association of prenatal exposure to benzodiazepines with development of autism spectrum and attention- deficit/hyperactivity disorders.<i> JAMA Netw Open</i>. 2022;5(11):e2243282. doi:10.1001/jamanetworkopen.2022.43282<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/36413366/pubmed" id="36413366" target="_blank">36413366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Choy.1">
<a name="Choy.1"></a>Choy Y. Acute procedural anxiety and specific phobia of clinical procedures in adults: Treatment overview. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 2, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9596205">
<a name="9596205"></a>Cloyd JC, Lalonde RL, Beniak TE, et al. A single-blind, crossover comparison of the pharmacokinetics and cognitive effects of a new diazepam rectal gel with intravenous diazepam. <i>Epilepsia</i>. 1998;39(5):520-526.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/9596205/pubmed" id="9596205" target="_blank">9596205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1190825">
<a name="1190825"></a>Cole AP, Hailey DM. Diazepam and active metabolite in breast milk and their transfer to the neonate. <i>Arch Dis Child</i>. 1975;50(9):741-742.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/1190825/pubmed" id="1190825" target="_blank">1190825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Craske.1">
<a name="Craske.1"></a>Craske M, Bystritsky A. Generalized anxiety disorder in adults: Management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23985170">
<a name="23985170"></a>Davanzo R, Dal Bo S, Bua J, Copertino M, Zanelli E, Matarazzo L. Antiepileptic drugs and breastfeeding. <i>Ital J Pediatr</i>. 2013;39:50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/23985170/pubmed" id="23985170" target="_blank">23985170</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Delgado.1">
<a name="Delgado.1"></a>Delgado J. Intoxication from LSD and other common hallucinogens. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 7, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bausch.1">
<a name="Bausch.1"></a>Diastat and Diastat AcuDial (diazepam) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.1">
<a name="Hospira.1"></a>Diazepam carpuject [prescribing information]. Lake Forest, IL: Hospira; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dash.1">
<a name="Dash.1"></a>Diazepam injection multi-dose vial [prescribing information]. Upper Saddle River, NJ: DASH Pharmaceuticals, LLC; July 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dash.2">
<a name="Dash.2"></a>Diazepam injection prefilled syringe [prescribing information]. Upper Saddle River, NJ: DASH Pharmaceuticals, LLC; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WestWard.1">
<a name="WestWard.1"></a>Diazepam Intensol (diazepam) [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals Corp; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Meridian.1">
<a name="Meridian.1"></a>Diazepam intramuscular autoinjector [prescribing information]. Columbia, MD: Meridian Medical Technologies; July 2005.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WestWard.2">
<a name="WestWard.2"></a>Diazepam oral solution [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals Corp; January 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WestWard.3">
<a name="WestWard.3"></a>Diazepam oral solution and Diazepam Intensol oral solution concentrate [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals Corp; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18998740">
<a name="18998740"></a>Dolder CR, Nelson MH. Hypnosedative-induced complex behaviours: incidence, mechanisms and management.<i> CNS Drugs.</i> 2008;22(12):1021-1036. doi:10.2165/0023210-200822120-00005.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/18998740/pubmed" id="18998740" target="_blank">18998740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Drappatz.1">
<a name="Drappatz.1"></a>Drappatz J, Avila EK. Seizures in patients with primary and metastatic brain tumors. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 19, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Drislane.1">
<a name="Drislane.1"></a>Drislane FW. Convulsive status epilepticus in adults: Management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 7, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2105100">
<a name="2105100"></a>Dusci LJ, Good SM, Hall RW, Ilett KF. Excretion of diazepam and its metabolites in human milk during withdrawal from combination high dose diazepam and oxazepam. <i>Br J Clin Pharmacol</i>. 1990;29(1):123-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/2105100/pubmed" id="2105100" target="_blank">2105100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5339679">
<a name="5339679"></a>Engle HA, “The Effect of Diazepam (Valium) in Children With Cerebral Palsy: A Double-Blind Study,” <i>Dev Med Child Neurol</i>, 1966, 8(6):661-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/5339679/pubmed" id="5339679" target="_blank">5339679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4113217">
<a name="4113217"></a>Erkkola R, Kanto J. Diazepam and breast-feeding. <i>Lancet</i>. 1972;1(7762):1235-1236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/4113217/pubmed" id="4113217" target="_blank">4113217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11973494">
<a name="11973494"></a>Everitt IJ, Barnett P. Comparison of two benzodiazepines used for sedation of children undergoing suturing of a laceration in an emergency department.<i> Pediatr Emerg Care</i>. 2002;18(2):72-74.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/11973494/pubmed" id="11973494" target="_blank">11973494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3970333">
<a name="3970333"></a>Fell D, Gough MB, Northan AA, Henderson CU. Diazepam premedication in children. Plasma levels and clinical effects. <i>Anaesthesia</i>. 1985;40(1):12-17.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/3970333/pubmed" id="3970333" target="_blank">3970333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29958100">
<a name="29958100"></a>Freeman MP, Góez-Mogollón L, McInerney KA, et al. Obstetrical and neonatal outcomes after benzodiazepine exposure during pregnancy: results from a prospective registry of women with psychiatric disorders. <i>Gen Hosp Psychiatry.</i> 2018;53:73-79. doi:10.1016/j.genhosppsych.2018.05.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/29958100/pubmed" id="29958100" target="_blank">29958100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Furman.1">
<a name="Furman.1"></a>Furman JM, Barton JJS. Treatment of vertigo. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 28, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gal.2007">
<a name="Gal.2007"></a>Gal P, Reed M. Medications. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007: 2955-2999.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1473667">
<a name="1473667"></a>Ginsberg GG, Lewis JH, Gallagher JE, et al. Diazepam versus midazolam for colonoscopy: a prospective evaluation of predicted versus actual dosing requirements. <i>Gastrointest Endosc</i>. 1992;38(6):651-656. doi: 10.1016/s0016-5107(92)70559-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/1473667/pubmed" id="1473667" target="_blank">1473667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26900382">
<a name="26900382"></a>Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. <i>Epilepsy Curr</i>. 2016;16(1):48-61. doi:10.5698/1535-7597-16.1.48<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/26900382/pubmed" id="26900382" target="_blank">26900382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32900457">
<a name="32900457"></a>Graves L, Carson G, Poole N, et al. Guideline No. 405: Screening and counselling for alcohol consumption during pregnancy. <i>J Obstet Gynaecol Can.</i> 2020;42(9):1158-1173.e1. doi:10.1016/j.jogc.2020.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/32900457/pubmed" id="32900457" target="_blank">32900457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2702793">
<a name="2702793"></a>Greenblatt DJ, Ehrenberg BL, Gunderman J, et al. Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. <i>Clin Pharmacol Ther</i>. 1989a;45(4):356-365.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/2702793/pubmed" id="2702793" target="_blank">2702793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2512694">
<a name="2512694"></a>Greenblatt DJ, Harmatz JS, Friedman H, Locniskar A, Shader RI. A large-sample study of diazepam pharmacokinetics. <i>Ther Drug Monit</i>. 1989b;11(6):652-657.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/2512694/pubmed" id="2512694" target="_blank">2512694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4851053">
<a name="4851053"></a>Greenblatt DJ, Koch-Weser J. Clinical toxicity of chlordiazepoxide and diazepam in relation to serum albumin concentration: a report from the Boston Collaborative Drug Surveillance Program. <i>Eur J Clin Pharmacol</i>. 1974;7(4):259-262. doi:10.1007/BF00560341<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/4851053/pubmed" id="4851053" target="_blank">4851053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23789008">
<a name="23789008"></a>Griffin CE 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. <i>Ochsner J</i>. 2013;13(2):214-223.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/23789008/pubmed" id="23789008" target="_blank">23789008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31294935">
<a name="31294935"></a>Grigoriadis S, Graves L, Peer M, et al. Benzodiazepine use during pregnancy alone or in combination with an antidepressant and congenital malformations: systematic review and meta- analysis. <i>J Clin Psychiatry.</i> 2019;80(4):18r12412. doi:10.4088/JCP.18r12412<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/31294935/pubmed" id="31294935" target="_blank">31294935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12521357">
<a name="12521357"></a>Hain TC, Uddin M. Pharmacological treatment of vertigo. <i>CNS Drugs</i>. 2003;17(2):85-100. doi: 10.2165/00023210-200317020-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/12521357/pubmed" id="12521357" target="_blank">12521357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2179901">
<a name="2179901"></a>Hall WC, Talbert RL, Ereshefsky L. Cocaine abuse and its treatment. <i>Pharmacotherapy</i>. 1990;10(1):47-65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/2179901/pubmed" id="2179901" target="_blank">2179901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19398681">
<a name="19398681"></a>Harden CL, Meador KJ, Pennell PB, et al, "Practice Parameter Update: Management Issues for Women With Epilepsy-Focus on Pregnancy (an Evidence-Based Review): Teratogenesis and Perinatal Outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society," <i>Neurology</i>, 2009, 73(2):133-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/19398681/pubmed" id="19398681" target="_blank">19398681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18245435">
<a name="18245435"></a>Hegenbarth MA and the American Academy of Pediatrics Committee on Drugs, “Preparing for Pediatric Emergencies: Drugs to Consider,” <i>Pediatrics</i>, 2008, 121(2):433-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/18245435/pubmed" id="18245435" target="_blank">18245435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hoffman.1">
<a name="Hoffman.1"></a>Hoffman RS. Management of moderate and severe alcohol withdrawal syndromes. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 2, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5317889">
<a name="5317889"></a>Holt KS. The use of diazepam in childhood cerebral palsy. Report of a small study including electromyographic observations. <i>Ann Phys Med</i>. 1964;Suppl:16-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/5317889/pubmed" id="5317889" target="_blank">5317889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Holt.1">
<a name="Holt.1"></a>Holt SR, Tetrault JM. Alcohol withdrawl: Ambulatory management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 2, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15192356">
<a name="15192356"></a>Hurst S and McMillan M, “Innovative Solutions in Critical Care Units: Extravasation Guidelines,” <i>Dimens Crit Care Nurs</i>, 2004, 23(3):125-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/15192356/pubmed" id="15192356" target="_blank">15192356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278. doi: 10.1542/peds.99.2.268.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11773648">
<a name="11773648"></a>Iqbal MM, Sobhan T, Ryals T, et al, "Effects of Commonly Used Benzodiazepines on the Fetus, the Neonate, and the Nursing Infant," <i>Psychiatr Serv</i>, 2002, 53(1):39-49.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/11773648/pubmed" id="11773648" target="_blank">11773648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26342397">
<a name="26342397"></a>Jennum P, Baandrup L, Ibsen R, Kjellberg J. Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: a population-based register study. <i>Eur Neuropsychopharmacol</i>. 2015;25(11):1906-1913. doi: 10.1016/j.euroneuro.2015.08.014.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/26342397/pubmed" id="26342397" target="_blank">26342397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6124415">
<a name="6124415"></a>Kanto JH. Use of benzodiazepines during pregnancy, labour and lactation, with particular reference to pharmacokinetic considerations. <i>Drugs</i>. 1982;23(5):354-380. doi:10.2165/00003495-198223050-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/6124415/pubmed" id="6124415" target="_blank">6124415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25081580">
<a name="25081580"></a>Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M; Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des Troubles Anxieux and McGill University. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. <i>BMC Psychiatry</i>. 2014;14(suppl 1):S1. doi: 10.1186/1471-244X-14-S1-S1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/25081580/pubmed" id="25081580" target="_blank">25081580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23553148">
<a name="23553148"></a>Kishimoto S, Nakamura K, Arai T, Yukimasa O, Fukami N. Postoperative neuroleptic malignant syndrome-like symptoms improved with intravenous diazepam: a case report. <i>J Anesth</i>. 2013;27(5):768-770. doi: 10.1007/s00540-013-1602-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/23553148/pubmed" id="23553148" target="_blank">23553148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10776831">
<a name="10776831"></a>Kita M, Goodkin DE. Drugs used to treat spasticity. <i>Drugs</i>. 2000;59(3):487-495. doi: 10.2165/00003495-200059030-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/10776831/pubmed" id="10776831" target="_blank">10776831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.2">
<a name="Kliegman.2"></a>Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16517277">
<a name="16517277"></a>Krauss B, Green SM. Procedural sedation and analgesia in children. <i>Lancet.</i> 2006;367(9512):766-780.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/16517277/pubmed" id="16517277" target="_blank">16517277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21714826">
<a name="21714826"></a>Lader M. Benzodiazepines revisited--will we ever learn? <i>Addiction</i>. 2011;106(12):2086-2109. doi:10.1111/j.1360-0443.2011.03563.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/21714826/pubmed" id="21714826" target="_blank">21714826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21721594">
<a name="21721594"></a>Lamson MJ, Sitki-Green D, Wannarka GL, Mesa M, Andrews P, Pellock J. Pharmacokinetics of diazepam administered intramuscularly by autoinjector versus rectal gel in healthy subjects: a phase I, randomized, open-label, single-dose, crossover, single-centre study. <i>Clin Drug Investig</i>. 2011;31(8):585-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/21721594/pubmed" id="21721594" target="_blank">21721594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26071998">
<a name="26071998"></a>Leppik IE, Patel SI. Intramuscular and rectal therapies of acute seizures. <i>Epilepsy Behav</i>. 2015;49:307-312. doi: 10.1016/j.yebeh.2015.05.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/26071998/pubmed" id="26071998" target="_blank">26071998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18180661">
<a name="18180661"></a>Ling Ngan Wong A, Tsz Fung Cheung I, Graham CA. Hydroxychloroquine overdose: case report and recommendations for management. <i>Eur J Emerg Med</i>. 2008;15(1):16-18. doi:10.1097/MEJ.0b013e3280adcb56<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/18180661/pubmed" id="18180661" target="_blank">18180661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15460178">
<a name="15460178"></a>Mancuso CE, Tanzi MG, Gabay M. Paradoxical reactions to benzodiazepines: literature review and treatment options. <i>Pharmacotherapy</i>. 2004;24(9):1177-1185. doi: 10.1592/phco.24.13.1177.38089.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/15460178/pubmed" id="15460178" target="_blank">15460178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11555803">
<a name="11555803"></a>Marquardt K, Albertson TE. Treatment of hydroxychloroquine overdose. <i>Am J Emerg Med</i>. 2001;19(5):420-424. doi:10.1053/ajem.2001.25774<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/11555803/pubmed" id="11555803" target="_blank">11555803</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12142810">
<a name="12142810"></a>Martinez JL, Sutters KA, Waite S, et al. A comparison of oral diazepam versus midazolam, administered with intravenous meperidine, as premedication to sedation for pediatric endoscopy. <i>J Pediatr Gastroenterol Nutr</i>. 2002;35(1):51-58.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/12142810/pubmed" id="12142810" target="_blank">12142810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15840761">
<a name="15840761"></a>Mathew A, Mathew MC, Thomas M, et al, “The Efficacy of Diazepam in Enhancing Motor Function in Children With Spastic Cerebral Palsy,” <i>J Trop Pediatr</i>, 2005, 51(2):109-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/15840761/pubmed" id="15840761" target="_blank">15840761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28440103">
<a name="28440103"></a>McAllister-Williams RH, Baldwin DS, Cantwell R, et al. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. <i>J Psychopharmacol.</i> 2017;31(5):519-552. doi:10.1177/0269881117699361<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/28440103/pubmed" id="28440103" target="_blank">28440103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26351590">
<a name="26351590"></a>McBeth PB, Missirlis PI, Brar H, Dhingra V. Novel therapies for myocardial irritability following extreme hydroxychloroquine toxicity. <i>Case Rep Emerg Med</i>. 2015;2015:692948. doi:10.1155/2015/692948<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/26351590/pubmed" id="26351590" target="_blank">26351590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7881198">
<a name="7881198"></a>McElhatton PR. The effects of benzodiazepine use during pregnancy and lactation. <i>Reprod Toxicol</i>. 1994;8(6):461-475.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/7881198/pubmed" id="7881198" target="_blank">7881198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7737034">
<a name="7737034"></a>Milsap RL, Jusko WJ. Pharmacokinetics in the infant. <i>Environ Health Perspect</i>. 1994;102 Suppl 11:107-110.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/7737034/pubmed" id="7737034" target="_blank">7737034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33224688">
<a name="33224688"></a>Moore TA. Ambulatory detoxification in alcohol use disorder and opioid use disorder. <i>Ment Health Clin</i>. 2020;10(6):307-316. doi:10.9740/mhc.2020.11.307<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/33224688/pubmed" id="33224688" target="_blank">33224688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Morselli.1">
<a name="Morselli.1"></a>Morselli PL, Franco-Morselli R, Bossi L. Clinical pharmacokinetics in newborns and infants. Age-related differences and therapeutic implications. <i>Clin Pharmacokinet</i>. 1980;5(6):485-527.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Morselli.2">
<a name="Morselli.2"></a>Morselli PL, Principi N, Tognoni G, et al. Diazepam elimination in premature and full term infants, and children. <i>J Perinat Med</i>. 1973;1(2):133-141.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moskowitz.1">
<a name="Moskowitz.1"></a>Moskowitz HS, Dinces EA. Meniere disease: Evaluation, diagnosis, and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 2, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10519733">
<a name="10519733"></a>Nelson J, Chouinard G. Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology. <i>Can J Clin Pharmacol</i>. 1999;6(2):69-83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/10519733/pubmed" id="10519733" target="_blank">10519733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35235572">
<a name="35235572"></a>Noh Y, Lee H, Choi A, et al. First-trimester exposure to benzodiazepines and risk of congenital malformations in offspring: a population-based cohort study in South Korea. <i>PLoS Med.</i> 2022;19(3):e1003945. doi:10.1371/journal.pmed.1003945<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/35235572/pubmed" id="35235572" target="_blank">35235572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7340884">
<a name="7340884"></a>Ochs HR, Greenblatt DJ, Kaschell HJ, Klehr U, Divoll M, Abernethy DR. Diazepam kinetics in patients with renal insufficiency or hyperthyroidism. <i>Br J Clin Pharmacol</i>. 1981;12(6):829-832. doi:10.1111/j.1365-2125.1981.tb01315.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/7340884/pubmed" id="7340884" target="_blank">7340884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6145109">
<a name="6145109"></a>Ochs HR, Rauh HW, Greenblatt DJ, Kaschell HJ. Clorazepate dipotassium and diazepam in renal insufficiency: serum concentrations and protein binding of diazepam and desmethyldiazepam. <i>Nephron</i>. 1984;37(2):100-104. doi:10.1159/000183222<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/6145109/pubmed" id="6145109" target="_blank">6145109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Olek.1">
<a name="Olek.1"></a>Olek MJ, Narayan RN, Frohman EM, Frohman TC. Symptom management of multiple sclerosis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 6, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Park.1">
<a name="Park.1"></a>Park TW. Benzodiazepine use disorder. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4110044">
<a name="4110044"></a>Patrick MJ, Tilstone WJ, Reavey P. Diazepam and breast-feeding. <i>Lancet</i>. 1972;1(7749):542-543.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/4110044/pubmed" id="4110044" target="_blank">4110044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20101040">
<a name="20101040"></a>Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society, Delgado MR, Hirtz D, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. <i>NeurologyR</i>. 2010;74(4):336-343.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/20101040/pubmed" id="20101040" target="_blank">20101040</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28259732">
<a name="28259732"></a>Radojčić MR, El Marroun H, Miljković B, et al. Prenatal exposure to anxiolytic and hypnotic medication in relation to behavioral problems in childhood: a population-based cohort study. <i>Neurotoxicol Teratol</i>. 2017;61:58-65. doi:10.1016/j.ntt.2017.02.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/28259732/pubmed" id="28259732" target="_blank">28259732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1547766">
<a name="1547766"></a>Remy C, Jourdil N, Villemain D, Favel P, Genton P. Intrarectal diazepam in epileptic adults. <i>Epilepsia</i>. 1992;33(2):353-358. doi: 10.1111/j.1528-1157.1992.tb02327.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/1547766/pubmed" id="1547766" target="_blank">1547766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3336379">
<a name="3336379"></a>Riou B, Barriot P, Rimailho A, Baud FJ. Treatment of severe chloroquine poisoning. <i>N Engl J Med</i>. 1988;318(1):1-6. doi:10.1056/NEJM198801073180101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/3336379/pubmed" id="3336379" target="_blank">3336379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Robertson.1">
<a name="Robertson.1"></a>Robertson CE, Eggers SDZ. Vestibular migraine. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 23, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8510706">
<a name="8510706"></a>Rosman NP, Colton T, Labazzo J, et al, “A Controlled Trial of Diazepam Administered During Febrile Illnesses to Prevent Recurrence of Febrile Seizures,” <i>N Engl J Med</i>, 1993, 329(2):79-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/8510706/pubmed" id="8510706" target="_blank">8510706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Roy-Byrne.1">
<a name="Roy-Byrne.1"></a>Roy-Byrne PP. Management of psychiatric disorders in patients with cancer. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 5, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29143367">
<a name="29143367"></a>Saarelainen L, Tolppanen AM, Koponen M, et al. Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: a matched cohort study. <i>Int J Geriatr Psychiatry.</i> 2018;33(4):583-590. doi: 10.1002/gps.4821.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/29143367/pubmed" id="29143367" target="_blank">29143367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27789115">
<a name="27789115"></a>Shih RD, Walsh B, Eskin B, et al. Diazepam and meclizine are equally effective in the treatment of vertigo: an emergency department randomized double-blind placebo-controlled trial. <i>J Emerg Med</i>. 2017;52(1):23-27. doi: 10.1016/j.jemermed.2016.09.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/27789115/pubmed" id="27789115" target="_blank">27789115</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28006997">
<a name="28006997"></a>Soyka M, Kranzler HR, Hesselbrock V, Kasper S, Mutschler J, Möller HJ; WFSBP Task Force on Treatment Guidelines for Substance Use Disorders. Guidelines for biological treatment of substance use and related disorders, part 1: alcoholism, first revision. <i>World J Biol Psychiatry</i>. 2017;18(2):86-119. doi: 10.1080/15622975.2016.1246752<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/28006997/pubmed" id="28006997" target="_blank">28006997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18519501">
<a name="18519501"></a>Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, "Febrile Seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures," <i>Pediatrics</i>, 2008, 121(6):1281-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/18519501/pubmed" id="18519501" target="_blank">18519501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy</i>. 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stolbach.2019">
<a name="Stolbach.2019"></a>Stolbach A, Hoffman RS. Opioid withdrawal in the emergency setting. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36520439">
<a name="36520439"></a>Sundbakk LM, Gran JM, Wood ME, Handal M, Skurtveit S, Nordeng H. Association of prenatal exposure to benzodiazepines and Z-hypnotics with risk of attention-deficit/hyperactivity disorder in childhood. <i>JAMA Netw Open</i>. 2022;5(12):e2246889. doi:10.1001/jamanetworkopen.2022.46889<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/36520439/pubmed" id="36520439" target="_blank">36520439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35909254">
<a name="35909254"></a>Szpunar MJ, Freeman MP, Kobylski LA, et al. Risk of major malformations in infants after first-trimester exposure to benzodiazepines: results from the Massachusetts General Hospital National Pregnancy Registry for Psychiatric Medications.<i> Depress Anxiety.</i> 2022;39(12):751-759. doi:10.1002/da.23280<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/35909254/pubmed" id="35909254" target="_blank">35909254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30632868">
<a name="30632868"></a>Thibaut F, Chagraoui A, Buckley L, et al. WFSBP and IAWMH guidelines for the treatment of alcohol use disorders in pregnant women.<i> World J Biol Psychiatry.</i> 2019;20(1):17-50. doi:10.1080/15622975.2018.1510185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/30632868/pubmed" id="30632868" target="_blank">30632868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24697803">
<a name="24697803"></a>Thomas SP, Thakkar J, Kovoor P, Thiagalingam A, Ross DL. Sedation for electrophysiological procedures.<i> Pacing Clin Electrophysiol</i>. 2014;37(6):781-790.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/24697803/pubmed" id="24697803" target="_blank">24697803</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30891943">
<a name="30891943"></a>Tinker SC, Reefhuis J, Bitsko RH, et al; National Birth Defects Prevention Study. Use of benzodiazepine medications during pregnancy and potential risk for birth defects, National Birth Defects Prevention Study, 1997-2011. <i>Birth Defects Res</i>. 2019;111(10):613-620. doi:10.1002/bdr2.1497<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/30891943/pubmed" id="30891943" target="_blank">30891943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30459031">
<a name="30459031"></a>Tormoehlen LM, Rusyniak DE. Neuroleptic malignant syndrome and serotonin syndrome. <i>Handb Clin Neurol</i>. 2018;157:663-675. doi: 10.1016/B978-0-444-64074-1.00039-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/30459031/pubmed" id="30459031" target="_blank">30459031</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23382625">
<a name="23382625"></a>Triantafillidis JK, Merikas E, Nikolakis D, Papalois AE. Sedation in gastrointestinal endoscopy: current issues. <i>World J Gastroenterol</i>. 2013;19(4):463-481.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/23382625/pubmed" id="23382625" target="_blank">23382625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20979709">
<a name="20979709"></a>Tsai MC, Huang TL. Severe neuroleptic malignant syndrome: successful treatment with high-dose lorazepam and diazepam: a case report. <i>Chang Gung Med J</i>. 2010;33(5):576-580.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/20979709/pubmed" id="20979709" target="_blank">20979709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23019837">
<a name="23019837"></a>Tyagi P, Dixit U, Tyagi S, Jain A. Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. <i>J Clin Pediatr Dent</i>. 2012;36(4):383-388.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/23019837/pubmed" id="23019837" target="_blank">23019837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VADOD.2">
<a name="VADOD.2"></a>US Department of Veterans Affairs/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the management of posttraumatic stress disorder and acute stress disorder. <a href="https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal.pdf</a>. Updated June 2017. Accessed March 9, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VADOD.1">
<a name="VADOD.1"></a>US Department of Veterans Affairs/US Department of Defense. VA/DoD clinical practice guideline for the management of substance use disorders. <a href="https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPG.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPG.pdf</a>. Published August 2021. Accessed May 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Roche.1">
<a name="Roche.1"></a>Valium (diazepam) [prescribing information]. Wixom, MI: Waylis Therapeutics LLC; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Neurelis.2">
<a name="Neurelis.2"></a>Valtoco (diazepam intranasal) [prescribing information]. San Diego, CA: Neurelis Inc; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22536226">
<a name="22536226"></a>Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABA(A) receptor modulators? <i>Adv Pharmacol Sci</i>. 2012;2012:416864. doi: 10.1155/2012/416864.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/22536226/pubmed" id="22536226" target="_blank">22536226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27824534">
<a name="27824534"></a>Wang RZ, Vashistha V, Kaur S, Houchens NW. Serotonin syndrome: preventing, recognizing, and treating it. <i>Cleve Clin J Med</i>. 2016;83(11):810-817. doi: 10.3949/ccjm.83a.15129<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/27824534/pubmed" id="27824534" target="_blank">27824534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35367514">
<a name="35367514"></a>Wang X, Zhang T, Ekheden I, et al. Prenatal exposure to benzodiazepines and Z-drugs in humans and risk of adverse neurodevelopmental outcomes in offspring: a systematic review. <i>Neurosci Biobehav Rev</i>. 2022;137:104647. doi:10.1016/j.neubiorev.2022.104647<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/35367514/pubmed" id="35367514" target="_blank">35367514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29325237">
<a name="29325237"></a>Ware MR, Feller DB, Hall KL. Neuroleptic malignant syndrome: diagnosis and management. <i>Prim Care Companion CNS Disord</i>. 2018;20(1):17r02185. doi: 10.4088/PCC.17r02185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/29325237/pubmed" id="29325237" target="_blank">29325237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28101764">
<a name="28101764"></a>Weintraub SJ. Diazepam in the treatment of moderate to severe alcohol withdrawal. <i>CNS Drugs</i>. 2017;31(2):87-95. doi: 10.1007/s40263-016-0403-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/28101764/pubmed" id="28101764" target="_blank">28101764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3920372">
<a name="3920372"></a>Wesson DR, Camber S, Harkey M, Smith DE. Diazepam and desmethyldiazepam in breast milk. <i>J Psychoactive Drugs</i>. 1985;17(1):55-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/3920372/pubmed" id="3920372" target="_blank">3920372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4033223">
<a name="4033223"></a>Wichliński LM, Mazur R, Sieradzki E, Jankowski A, Dirska R, Gosk-Kowalska T. Pharmacokinetics of diazepam after intravenous, intramuscular and oral administration to humans. <i>Mater Med Pol</i>. 1985;17(1):44-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/4033223/pubmed" id="4033223" target="_blank">4033223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29605483">
<a name="29605483"></a>Wightman RS, Nelson LS, Lee JD, Fox LM, Smith SW. Severe opioid withdrawal precipitated by Vivitrol®. <i>Am J Emerg Med</i>. 2018;36(6):1128.e1-1128.e2. doi: 10.1016/j.ajem.2018.03.052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/29605483/pubmed" id="29605483" target="_blank">29605483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wijdicks.2019">
<a name="Wijdicks.2019"></a>Wijdicks EFM. Neuroleptic malignant syndrome. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 14, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17894421">
<a name="17894421"></a>Wikner BN, Stiller CO, Bergman U, et al, "Use of Benzodiazepines and Benzodiazepine Receptor Agonists During Pregnancy: Neonatal Outcome and Congenital Malformations," <i>Pharmacoepidemiol Drug Saf</i>, 2007, 16(11):1203-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/17894421/pubmed" id="17894421" target="_blank">17894421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10991709">
<a name="10991709"></a>Wilson KC, Reardon C, Farber HW. Propylene glycol toxicity in a patient receiving intravenous diazepam. <i>N Engl J Med</i>. 2000;343(11):815.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/10991709/pubmed" id="10991709" target="_blank">10991709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16162774">
<a name="16162774"></a>Wilson KC, Reardon C, Theodore AC, et al. Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines: A case series and prospective, observational pilot study. <i>Chest.</i> 2005;128(3):1674-1681.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/16162774/pubmed" id="16162774" target="_blank">16162774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22711424">
<a name="22711424"></a>Wlodarczyk BJ, Palacios AM, George TM, et al, "Antiepileptic Drugs and Pregnancy Outcomes," <i>Am J Med Genet A</i>, 2012, 158A(8):2071-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/22711424/pubmed" id="22711424" target="_blank">22711424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28297728">
<a name="28297728"></a>Wodarz N, Krampe-Scheidler A, Christ M, et al. Evidence-based guidelines for the pharmacological management of acute methamphetamine-related disorders and toxicity. <i>Pharmacopsychiatry</i>. 2017;50(3):87-95. doi: 10.1055/s-0042-123752<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/28297728/pubmed" id="28297728" target="_blank">28297728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. https://apps.who.int/iris/handle/10665/62435.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.3">
<a name="WHO.3"></a>World Health Organization (WHO). Guidelines for the identification and management of substance use and substance use disorders in pregnancy. World Health Organization; 2014. <a href="https://www.ncbi.nlm.nih.gov/books/NBK200701/" target="_blank">https://www.ncbi.nlm.nih.gov/books/NBK200701/</a>. Accessed March 24, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization, WHO Technical Note. Current recommendations for the treatment of tetanus during humanitarian emergencies. January 2010. http://www.who.int/diseasecontrol_emergencies/who_hse_gar_dce_2010_en.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17933619">
<a name="17933619"></a>Wusthoff CJ, Shellhaas RA, Licht DJ. Management of common neurologic symptoms in pediatric palliative care: seizures, agitation, and spasticity. <i>Pediatr Clin North Am</i>. 2007;54(5):709-xi.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/17933619/pubmed" id="17933619" target="_blank">17933619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18657015">
<a name="18657015"></a>Yahwak JA, Riker RR, Fraser GL, Subak-Sharpe S. Determination of a lorazepam dose threshold for using the osmol gap to monitor for propylene glycol toxicity. <i>Pharmacotherapy</i>. 2008;28(8):984-991.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/18657015/pubmed" id="18657015" target="_blank">18657015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10343209">
<a name="10343209"></a>Zakko SF, Seifert HA, Gross JB. A comparison of midazolam and diazepam for conscious sedation during colonoscopy in a prospective double-blind study. <i>Gastrointest Endosc</i>. 1999;49(6):684-689. doi: 10.1016/s0016-5107(99)70282-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/10343209/pubmed" id="10343209" target="_blank">10343209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2216645">
<a name="2216645"></a>Zeltzer LK, Altman A, Cohen D, et al, “Report of the Subcommittee on the Management of Pain Associated With Procedures in Children With Cancer,” <i>Pediatrics</i>, 1990, 86(5 Pt 2):826-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazepam-drug-information/abstract-text/2216645/pubmed" id="2216645" target="_blank">2216645</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9345 Version 724.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
